

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Analysis of the health product pipeline for... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-416/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-416" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool" />
    
            <meta name="og:title" content="F1000Research Article: Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool.">
            <meta name="og:description" content="Read the latest article version by Shashika Bandara, Nick Chapman, Vipul Chowdhary, Anna Doubell, Amelia Hynen, George Rugarabamu, Alexander Gunn, Gavin Yamey, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="26491">
            <meta name="article-id" content="24015">
            <meta name="dc.title" content="Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool">
            <meta name="dc.description" content=" Background: To estimate how much additional funding is needed for poverty-related and neglected disease (PRND) product development and to target new resources effectively, policymakers need updated information on the development pipeline and estimated costs to fill pipeline gaps. 
 Methods: We previously conducted a pipeline review to identify candidates for 35 neglected diseases as of August 31, 2017 (&ldquo;2017 pipeline&rdquo;). We used the Portfolio-to-Impact (P2I) tool to estimate costs to move these candidates through the pipeline, likely launches, and additional costs to develop &ldquo;missing products.&rdquo; We repeated this analysis, reviewing the pipeline to August 31, 2019 to get a time trend. We made a direct comparison based on the same 35 diseases (&ldquo;2019 direct comparison pipeline&rdquo;), then a comparison based on an expanded list of 45 diseases (&ldquo;2019 complete pipeline&rdquo;). 
 Results: In the 2017 pipeline, 538 product candidates met inclusion criteria for input into the model; it would cost $16.3 billion (B) to move these through the pipeline, yielding 128 launches. In the 2019 direct comparison pipeline, we identified 690 candidates, an increase of 152 candidates from 2017; the largest increase was for Ebola. &amp;nbsp;The direct comparison 2019 pipeline yields 196 launches, costing $19.9B. In the 2019 complete pipeline, there were 754 candidates, an increase of 216 candidates from 2017, of which 152 reflected pipeline changes and 64 reflected changes in scope. The complete pipeline 2019 yields 207 launches, costing $21.0B. There would still be 16 &ldquo;missing products&rdquo; based on the complete 2019 pipeline; it would cost $5.5B-$14.2B (depending on product complexity) to develop these products. 
 Conclusion: The PRNDs product development pipeline has grown by over a quarter in two years. The number of expected new product launches based on the 2019 pipeline increased by half compared to 2017; the cost of advancing the pipeline increased by a quarter.">
            <meta name="dc.subject" content="neglected diseases, product development, emerging infections, research and development, research funding">
            <meta name="dc.creator" content="Bandara, Shashika">
            <meta name="dc.creator" content="Chapman, Nick">
            <meta name="dc.creator" content="Chowdhary, Vipul">
            <meta name="dc.creator" content="Doubell, Anna">
            <meta name="dc.creator" content="Hynen, Amelia">
            <meta name="dc.creator" content="Rugarabamu, George">
            <meta name="dc.creator" content="Gunn, Alexander">
            <meta name="dc.creator" content="Yamey, Gavin">
            <meta name="dc.date" content="2020/05/21">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.24015.1">
            <meta name="dc.source" content="F1000Research 2020 9:416">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="neglected diseases">
            <meta name="prism.keyword" content="product development">
            <meta name="prism.keyword" content="emerging infections">
            <meta name="prism.keyword" content="research and development">
            <meta name="prism.keyword" content="research funding">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/05/21">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="416">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.24015.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-416">
            <meta name="citation_title" content="Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool">
            <meta name="citation_abstract" content=" Background: To estimate how much additional funding is needed for poverty-related and neglected disease (PRND) product development and to target new resources effectively, policymakers need updated information on the development pipeline and estimated costs to fill pipeline gaps. 
 Methods: We previously conducted a pipeline review to identify candidates for 35 neglected diseases as of August 31, 2017 (&ldquo;2017 pipeline&rdquo;). We used the Portfolio-to-Impact (P2I) tool to estimate costs to move these candidates through the pipeline, likely launches, and additional costs to develop &ldquo;missing products.&rdquo; We repeated this analysis, reviewing the pipeline to August 31, 2019 to get a time trend. We made a direct comparison based on the same 35 diseases (&ldquo;2019 direct comparison pipeline&rdquo;), then a comparison based on an expanded list of 45 diseases (&ldquo;2019 complete pipeline&rdquo;). 
 Results: In the 2017 pipeline, 538 product candidates met inclusion criteria for input into the model; it would cost $16.3 billion (B) to move these through the pipeline, yielding 128 launches. In the 2019 direct comparison pipeline, we identified 690 candidates, an increase of 152 candidates from 2017; the largest increase was for Ebola. &amp;nbsp;The direct comparison 2019 pipeline yields 196 launches, costing $19.9B. In the 2019 complete pipeline, there were 754 candidates, an increase of 216 candidates from 2017, of which 152 reflected pipeline changes and 64 reflected changes in scope. The complete pipeline 2019 yields 207 launches, costing $21.0B. There would still be 16 &ldquo;missing products&rdquo; based on the complete 2019 pipeline; it would cost $5.5B-$14.2B (depending on product complexity) to develop these products. 
 Conclusion: The PRNDs product development pipeline has grown by over a quarter in two years. The number of expected new product launches based on the 2019 pipeline increased by half compared to 2017; the cost of advancing the pipeline increased by a quarter.">
            <meta name="citation_description" content=" Background: To estimate how much additional funding is needed for poverty-related and neglected disease (PRND) product development and to target new resources effectively, policymakers need updated information on the development pipeline and estimated costs to fill pipeline gaps. 
 Methods: We previously conducted a pipeline review to identify candidates for 35 neglected diseases as of August 31, 2017 (&ldquo;2017 pipeline&rdquo;). We used the Portfolio-to-Impact (P2I) tool to estimate costs to move these candidates through the pipeline, likely launches, and additional costs to develop &ldquo;missing products.&rdquo; We repeated this analysis, reviewing the pipeline to August 31, 2019 to get a time trend. We made a direct comparison based on the same 35 diseases (&ldquo;2019 direct comparison pipeline&rdquo;), then a comparison based on an expanded list of 45 diseases (&ldquo;2019 complete pipeline&rdquo;). 
 Results: In the 2017 pipeline, 538 product candidates met inclusion criteria for input into the model; it would cost $16.3 billion (B) to move these through the pipeline, yielding 128 launches. In the 2019 direct comparison pipeline, we identified 690 candidates, an increase of 152 candidates from 2017; the largest increase was for Ebola. &amp;nbsp;The direct comparison 2019 pipeline yields 196 launches, costing $19.9B. In the 2019 complete pipeline, there were 754 candidates, an increase of 216 candidates from 2017, of which 152 reflected pipeline changes and 64 reflected changes in scope. The complete pipeline 2019 yields 207 launches, costing $21.0B. There would still be 16 &ldquo;missing products&rdquo; based on the complete 2019 pipeline; it would cost $5.5B-$14.2B (depending on product complexity) to develop these products. 
 Conclusion: The PRNDs product development pipeline has grown by over a quarter in two years. The number of expected new product launches based on the 2019 pipeline increased by half compared to 2017; the cost of advancing the pipeline increased by a quarter.">
            <meta name="citation_keywords" content="neglected diseases, product development, emerging infections, research and development, research funding">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Shashika Bandara">
            <meta name="citation_author_institution" content="Center for Policy Impact in Global Health, Duke Global Health Institute, Duke University, Durham, NC, 27708, USA">
            <meta name="citation_author" content="Nick Chapman">
            <meta name="citation_author_institution" content="Policy Cures Research, Sydney, NSW, 2010, Australia">
            <meta name="citation_author" content="Vipul Chowdhary">
            <meta name="citation_author_institution" content="Policy Cures Research, Sydney, NSW, 2010, Australia">
            <meta name="citation_author" content="Anna Doubell">
            <meta name="citation_author_institution" content="Policy Cures Research, Sydney, NSW, 2010, Australia">
            <meta name="citation_author" content="Amelia Hynen">
            <meta name="citation_author_institution" content="Policy Cures Research, Sydney, NSW, 2010, Australia">
            <meta name="citation_author" content="George Rugarabamu">
            <meta name="citation_author_institution" content="Policy Cures Research, Sydney, NSW, 2010, Australia">
            <meta name="citation_author" content="Alexander Gunn">
            <meta name="citation_author_institution" content="Center for Policy Impact in Global Health, Duke Global Health Institute, Duke University, Durham, NC, 27708, USA">
            <meta name="citation_author" content="Gavin Yamey">
            <meta name="citation_author_institution" content="Center for Policy Impact in Global Health, Duke Global Health Institute, Duke University, Durham, NC, 27708, USA">
            <meta name="citation_publication_date" content="2020/05/21">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="416">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.24015.1">
            <meta name="citation_firstpage" content="416">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-416/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-416.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=26491 /> <input type=hidden id=articleId name=articleId value=24015 /> <input type=hidden id=xmlUrl value="/articles/9-416/v1/xml"/> <input type=hidden id=xmlFileName value="-9-416-v1.xml"> <input type=hidden id=article_uuid value=1fd567b5-6913-4351-9f42-422818aeb4ba /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.24015.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.24015.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-416"
  },
  "headline": "Analysis of the health product pipeline for poverty-related and neglected diseases using the...",
  "datePublished": "2020-05-21T14:52:22",
  "dateModified": "2020-05-21T14:52:22",
  "author": [
    {
      "@type": "Person",
      "name": "Shashika Bandara"
    },    {
      "@type": "Person",
      "name": "Nick Chapman"
    },    {
      "@type": "Person",
      "name": "Vipul Chowdhary"
    },    {
      "@type": "Person",
      "name": "Anna Doubell"
    },    {
      "@type": "Person",
      "name": "Amelia Hynen"
    },    {
      "@type": "Person",
      "name": "George Rugarabamu"
    },    {
      "@type": "Person",
      "name": "Alexander Gunn"
    },    {
      "@type": "Person",
      "name": "Gavin Yamey"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Background: To estimate how much additional funding is needed for poverty-related and neglected disease (PRND) product development and to target new resources effectively, policymakers need updated information on the development pipeline and estimated costs to fill pipeline gaps.
Methods: We previously conducted a pipeline review to identify candidates for 35 neglected diseases as of August 31, 2017 (&ldquo;2017 pipeline&rdquo;). We used the Portfolio-to-Impact (P2I) tool to estimate costs to move these candidates through the pipeline, likely launches, and additional costs to develop &ldquo;missing products.&rdquo; We repeated this analysis, reviewing the pipeline to August 31, 2019 to get a time trend. We made a direct comparison based on the same 35 diseases (&ldquo;2019 direct comparison pipeline&rdquo;), then a comparison based on an expanded list of 45 diseases (&ldquo;2019 complete pipeline&rdquo;).
Results: In the 2017 pipeline, 538 product candidates met inclusion criteria for input into the model; it would cost $16.3 billion (B) to move these through the pipeline, yielding 128 launches. In the 2019 direct comparison pipeline, we identified 690 candidates, an increase of 152 candidates from 2017; the largest increase was for Ebola.  The direct comparison 2019 pipeline yields 196 launches, costing $19.9B. In the 2019 complete pipeline, there were 754 candidates, an increase of 216 candidates from 2017, of which 152 reflected pipeline changes and 64 reflected changes in scope. The complete pipeline 2019 yields 207 launches, costing $21.0B. There would still be 16 &ldquo;missing products&rdquo; based on the complete 2019 pipeline; it would cost $5.5B-$14.2B (depending on product complexity) to develop these products.
Conclusion: The PRNDs product development pipeline has grown by over a quarter in two years. The number of expected new product launches based on the 2019 pipeline increased by half compared to 2017; the cost of advancing the pipeline increased by a quarter."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-416",
            "name": "Analysis of the health product pipeline for poverty-related and neglected..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Analysis of the health product pipeline for poverty-related and neglected... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=26491 data-id=24015 data-downloads="" data-views="" data-scholar="10.12688/f1000research.24015.1" data-recommended="" data-doi="10.12688/f1000research.24015.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-416/v1/pdf?article_uuid=1fd567b5-6913-4351-9f42-422818aeb4ba" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-24015-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-24015-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-24015-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Bandara S, Chapman N, Chowdhary V <em>et al.</em> Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool [version 1; peer review: awaiting peer review]</span>. <i>F1000Research</i> 2020, <b>9</b>:416 (<a class=new-orange href="https://doi.org/10.12688/f1000research.24015.1" target=_blank>https://doi.org/10.12688/f1000research.24015.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-24015-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=24015 id=track-article-signin-24015 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/24015?target=/articles/9-416">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=26491 /> <input name=articleId type=hidden value=24015 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Research Article </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool</h1><span class=other-info> [version 1; peer review: awaiting peer review]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Shashika Bandara<sup>1</sup>,&nbsp;</span><span class="">Nick Chapman<sup>2</sup>,&nbsp;</span><span class="">Vipul Chowdhary<sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Anna Doubell<sup>2</sup>,&nbsp;</span><span class=article-page-hidden-authors>Amelia Hynen<sup>2</sup>,&nbsp;</span><span class="">George Rugarabamu<sup>2</sup>,&nbsp;</span><span class="">Alexander Gunn<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:gavin.yamey@duke.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Gavin Yamey</span></a><a href="https://orcid.org/0000-0002-8390-7382" target=_blank id=author-orcid-7><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-7><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8390-7382</div><sup>1</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Shashika Bandara<sup>1</sup>,&nbsp;</span><span class="">Nick Chapman<sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Vipul Chowdhary<sup>2</sup>,&nbsp;</span><span class=article-page-hidden-authors>Anna Doubell<sup>2</sup>,&nbsp;</span><span class=article-page-hidden-authors>Amelia Hynen<sup>2</sup>,&nbsp;</span><span class=article-page-hidden-authors>George Rugarabamu<sup>2</sup>,&nbsp;</span><span class="">Alexander Gunn<sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:gavin.yamey@duke.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Gavin Yamey</span></a><a href="http://orcid.org/0000-0002-8390-7382" target=_blank id=mauthor-orcid-7><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-7><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8390-7382</div><sup>1</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 21 May 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.24015.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Center for Policy Impact in Global Health, Duke Global Health Institute, Duke University, Durham, NC, 27708, USA<br/> <sup>2</sup> Policy Cures Research, Sydney, NSW, 2010, Australia<br/> <p> <div class=margin-bottom> Shashika Bandara <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Review & Editing </div> <div class=margin-bottom> Nick Chapman <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Vipul Chowdhary <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Validation, Writing – Review & Editing </div> <div class=margin-bottom> Anna Doubell <br/> <span>Roles: </span> Conceptualization, Investigation, Methodology, Project Administration, Visualization, Writing – Review & Editing </div> <div class=margin-bottom> Amelia Hynen <br/> <span>Roles: </span> Conceptualization, Data Curation, Investigation, Methodology, Writing – Review & Editing </div> <div class=margin-bottom> George Rugarabamu <br/> <span>Roles: </span> Conceptualization, Data Curation, Investigation, Methodology, Validation, Writing – Review & Editing </div> <div class=margin-bottom> Alexander Gunn <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – Review & Editing </div> <div class=margin-bottom> Gavin Yamey <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <em>AWAITING PEER REVIEW</em> </span> </div> </div> </div> <div class="f1r-article-desk padding-top"> <div class=article-collection-wrapper> <div class="o-media o-media--sm o-media--center"> <div class=o-media__img> <a href="https://f1000research.com/gateways/tdr" title="Open Gateway"><img src="https://f1000researchdata.s3.amazonaws.com/thumbnails/abeb2fd8-f83b-4842-8bdf-8e7f2f7dcb03_collection.thumbnail"></a> </div> <div class=o-media__body> <p class="u-mt--0 u-mb--0">This article is included in the <a href="https://f1000research.com/gateways/tdr">TDR</a> gateway.</p> </div> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> <b>Background: </b>To estimate how much additional funding is needed for poverty-related and neglected disease (PRND) product development and to target new resources effectively, policymakers need updated information on the development pipeline and estimated costs to fill pipeline gaps.<br/> <b>Methods: </b>We previously conducted a pipeline review to identify candidates for 35 neglected diseases as of August 31, 2017 (“2017 pipeline”). We used the Portfolio-to-Impact (P2I) tool to estimate costs to move these candidates through the pipeline, likely launches, and additional costs to develop “missing products.” We repeated this analysis, reviewing the pipeline to August 31, 2019 to get a time trend. We made a direct comparison based on the same 35 diseases (“2019 direct comparison pipeline”), then a comparison based on an expanded list of 45 diseases (“2019 complete pipeline”).<br/> <b>Results:</b> In the 2017 pipeline, 538 product candidates met inclusion criteria for input into the model; it would cost $16.3 billion (B) to move these through the pipeline, yielding 128 launches. In the 2019 direct comparison pipeline, we identified 690 candidates, an increase of 152 candidates from 2017; the largest increase was for Ebola. &nbsp;The direct comparison 2019 pipeline yields 196 launches, costing $19.9B. In the 2019 complete pipeline, there were 754 candidates, an increase of 216 candidates from 2017, of which 152 reflected pipeline changes and 64 reflected changes in scope. The complete pipeline 2019 yields 207 launches, costing $21.0B. There would still be 16 “missing products” based on the complete 2019 pipeline; it would cost $5.5B-$14.2B (depending on product complexity) to develop these products.<br/> <b>Conclusion: </b>The PRNDs product development pipeline has grown by over a quarter in two years. The number of expected new product launches based on the 2019 pipeline increased by half compared to 2017; the cost of advancing the pipeline increased by a quarter. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> neglected diseases, product development, emerging infections, research and development, research funding </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Gavin Yamey (<a href="mailto:gavin.yamey@duke.edu">gavin.yamey@duke.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Gavin Yamey </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> SB, AG, and GY declares that the Center for Policy Impact in Global Health has received research support from the Bill & Melinda Gates Foundation, the WHO, Gavi, the Vaccine Alliance, and the Global Health Technologies Coalition, all of whom support efforts to develop neglected disease products. AG declares that he has no competing interests. NC, VC, AD, AH and GR declare that the organization they work for (Policy Cures Research) has received research support from the Bill & Melinda Gates Foundation, the WHO, the Wellcome Trust, PATH, and the Global Health Technologies Coalition, all of whom support efforts to develop neglected disease products. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> TDR: the Special Programme for Research and Training in Tropical Diseases [TDR project ID number B80154]. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Bandara S <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Bandara S, Chapman N, Chowdhary V <em>et al.</em> Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool [version 1; peer review: awaiting peer review]</span>. <i>F1000Research</i> 2020, <b>9</b>:416 (<a href="https://doi.org/10.12688/f1000research.24015.1" target=_blank>https://doi.org/10.12688/f1000research.24015.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 21 May 2020, <b>9</b>:416 (<a href="https://doi.org/10.12688/f1000research.24015.1" target=_blank>https://doi.org/10.12688/f1000research.24015.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 21 May 2020, <b>9</b>:416 (<a href="https://doi.org/10.12688/f1000research.24015.1" target=_blank>https://doi.org/10.12688/f1000research.24015.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d28479e255>Introduction</h2><p class="" id=d28479e258>A growing body of evidence has shown that the ambitious global health goals established by the international health community, including the health-related Sustainable Development Goals (SDGs), are unlikely to be achieved with today’s health technologies alone<sup><a href="#ref-1">1</a>–<a href="#ref-4">4</a></sup>. New breakthrough technologies will be needed to accelerate the current rate of mortality reduction.</p><p class="" id=d28479e268>For example, the 2013 report of the <i>Lancet</i> Commission on Investing in Health (CIH) showed that the development and widespread deployment of new technologies would be needed to achieve a “grand convergence” in global health<sup><a href="#ref-1">1</a></sup>. The CIH defined grand convergence as a universal reduction in deaths from infections and maternal and child health conditions down to the mortality levels achieved in 2011 by the best-performing middle-income countries (e.g. China and Chile)<sup><a href="#ref-1">1</a></sup>. Unfortunately, progress on mortality from several conditions has been slow since this report<i></i> was published. If the global trends in maternal mortality and mortality from tuberculosis (TB) achieved in 2010–16 were to continue, the convergence targets would not be achieved until 2067 for maternal mortality and 2074 for TB mortality, respectively<sup><a href="#ref-4">4 </a></sup>. This slow progress underscores the need for new medicines, vaccines, diagnostics, and other disease control tools.</p><p class="" id=d28479e288>There are several signs suggesting that policymakers at global and national levels do recognize the importance of funding product development for poverty-related and neglected diseases. First, funding levels for health research and development (R&amp;D) were included in the <a target=xrefwindow href="https://www.who.int/research-observatory/indicators/en/" id=d28479e290>indicators that are linked to the SDG health targets</a>. For example, SDG Indicator 3.b.2 includes “official development assistance (ODA) for medical research and basic health sectors as a % of gross national income (GNI) and as a % of all ODA, by donor country.” SDG Indicator 9.5.1 is “gross domestic R&amp;D expenditure on health (health GERD) as a % of gross domestic product (GDP).” Second, the new <a target=xrefwindow href="https://www.who.int/sdg/global-action-plan" id=d28479e293>Global Action Plan for Healthy Lives and Wellbeing for All</a>, which commits 12 multilateral health and development organizations to improving their collaboration on achieving the SDGs, includes an effort to scale up health R&amp;D. Third, several new initiatives have been launched in recent years to mobilize additional funding for global health product development, such as the Global Health Innovative Technology Fund and the Coalition for Epidemic Preparedness Innovations<sup><a href="#ref-5">5</a></sup>. Fourth, a number of new global health R&amp;D coordination mechanisms have also been launched, such as the Global Antimicrobial Resistance R&amp;D Hub and the World Health Organization’s Global Observatory on Health R&amp;D<sup><a href="#ref-5">5</a></sup>.</p><p class="" id=d28479e305>To estimate how much additional funding is needed for global health product development and to target any new resources effectively, policymakers need up-to-date information on the status of the development pipeline and the estimated costs to fill gaps in the pipeline. In particular, as we have previously argued, they need information on “which candidates are currently in the pipeline and at what development phase; the estimated costs to accelerate this portfolio of candidates to production; the anticipated product launches that would result from such acceleration; and the critical, highly needed products that would still be “missing” under the status quo.”<sup><a href="#ref-6">6</a></sup></p><p class="" id=d28479e312>In order to generate such information, in 2018 we published the first ever study to use a new financial modeling tool, called the Portfolio-to-Impact (P2I) tool, that can be used to estimate the costs of moving a portfolio of candidates along the pipeline<sup><a href="#ref-6">6</a></sup>. In that 2018 study, we first conducted a comprehensive, rigorous pipeline portfolio review to identify product candidates for 35 neglected diseases as of August 31, 2017. We found 538 candidates that met inclusion criteria for input into the modeling tool. Using this tool, we estimated that it would cost about $16.3 billion (range $13.4B-19.8B) to move these 538 candidates through the pipeline, with three-quarters of the costs incurred in the first 5 years, resulting in about 128 (89-160) expected product launches by 2029. </p><p class="" id=d28479e319>Among these launches, our modeling suggested that there would be few launches of complex new chemical entities (NCEs). We also found that, based on the pipeline as of August 31, 2017, launches of highly efficacious HIV, TB, or malaria vaccines would be unlikely. We estimated that the additional costs to launch one of each of 18 priority “missing” products would be $13.6B, assuming lowest product complexity or $21.8B assuming highest complexity ($8.1B-36.6B).</p><p class="" id=d28479e322>In this current study, we have conducted a new pipeline portfolio review and we have updated the cost modeling. There are several reasons why this updated study was needed. First, the product development pipeline is never static—it changes frequently—and so we wanted to gain an understanding of how the pipeline has changed. We conducted a new pipeline review up to August 31, 2019, i.e. exactly two years on from our last study, allowing us to show how much change can be expected over such a two-year period. Second, we wanted to assess whether the prospects have improved for launching critically needed products, such as vaccines for HIV, TB, and malaria. Third, our new study was timely given the launch of a new target product profile (TPP) directory developed by the Special Programme for Research and Training in Tropical Diseases (TDR). We hoped that we could potentially compare our new findings on product gaps with the gaps identified in the new TPP directory. Finally, we wanted the new findings to help identify the most promising ways in which the pipeline can be better managed to accelerate the development and deployment of critically needed health technologies for poverty-related and neglected diseases.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28479e328>Methods</h2><p class="" id=d28479e331>In this section, we begin, in sub-section (i), by summarizing the development of the P2I tool. While the tool development has previously been published in detail<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>, we wanted to summarize the key steps so that readers could understand the underlying principles of—and the assumptions and data sources underlying—the tool. In sub-section (ii), we describe how we conducted the pipeline portfolio review and in (iii) we explain how we classified each candidate into its product type (which we call “archetype”, e.g. simple NCE, complex NCE). In sub-section (iv) we describe how we inputted the pipeline of candidates into the P2I model. In sub-section (v), we explain how we estimated the costs of priority “missing” products. Finally, in sub-section (vi), we describe our sensitivity analysis.</p><div class=section><a name=d28479e341 class=n-a></a><h3 class=section-title>(i) Summary of how the P2I.v2 model was developed</h3><p class="" id=d28479e346>The P2I model is a deterministic modeling tool that enables users to estimate funding needs to move a portfolio of candidate health products through the pipeline from advanced preclinical to phase III clinical trials, as well as potential product launches over time. The first version of the P2I tool, called P2I version 1 (P2I.v1) is a Microsoft Excel-based tool that is freely available online<sup><a href="#ref-7">7</a></sup>. In the first study to apply this tool to the pipeline of candidate products for neglected diseases, we made a number of adaptations to P2I.v1, and called the adapted version P2I version 2 (P2I.v2); this adapted version is also an open access Microsoft Excel-based tool<sup><a href="#ref-6">6</a></sup>. Both the P2I.v1 and P2I.v2 models are based on assumptions for costs, attrition rates (probability of success), and cycle times per phase for four phases of research—advanced preclinical to phase III—for different product types (archetypes). <a href="#f1">Figure 1</a> shows a conceptual overview of the P2I model, and <a href="#f2">Figure 2</a> shows which phases are included.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/26491/f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure1.gif"><img alt="f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/26491/f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure1.gif"></a><div class=caption><h3>Figure 1. Conceptual overview of the P2I model.</h3><p id=d28479e373>This figure is taken with permission from Young R, Bekele T, Gunn A <i>et al.</i> Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. Gates Open Research 2018, 2:23.</p></div></div><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/26491/f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure2.gif"><img alt="f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/26491/f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure2.gif"></a><div class=caption><h3>Figure 2. Development phases included in the P2I model.</h3><p id=d28479e393>This figure has been adapted with permission from Health Product Research and Development Fund: A Proposal for Financing and Operation. WHO/TDR, 2016.</p></div></div><p class="" id=d28479e400>The P2I.v1 model has 11 archetypes: simple or complex vaccines; simple or complex NCEs; simple, innovative, or complex repurposed drugs; simple or complex biologics; and two diagnostic archetypes—assay development or simple technical platform development. We made a number of adaptations in the development of P2I.v2, including the addition of “unprecedented vaccines” (for HIV, TB, and malaria) and vector control products. <a href="#T1">Table 1</a> describes the 14 archetypes in the P2I.v2 model, which is the version we have used in this new study.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Descriptions and examples of the 14 archetypes included in the P2I.v2 model.</h3><p id=d28479e417>Adapted from Young <i>et al</i>. (2018)<sup><a href="#ref-6">6</a></sup> under the terms of the <a target=xrefwindow href="https://creativecommons.org/licenses/by/4.0/legalcode" id=d28479e426>Creative Commons Attribution 4.0 International license</a> (CC-BY 4.0).</p></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e431 class=n-a></a><thead><a name=d28479e433 class=n-a></a><tr><a name=d28479e435 class=n-a></a><th align=left colspan=2 rowspan=1 valign=middle><a name=d28479e437 class=n-a></a>Product archetype</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e440 class=n-a></a>Description</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e443 class=n-a></a>Examples</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e446 class=n-a></a>Further definition</th></tr></thead><tbody><a name=d28479e451 class=n-a></a><tr><a name=d28479e453 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d28479e455 class=n-a></a><b>Repurposed</b><br class=br><b>drug</b></td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e462 class=n-a></a>Simple</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e465 class=n-a></a>Drug has sufficient<br class=br>safety data to start<br class=br>development in phase<br class=br>II</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e474 class=n-a></a>azithromycin, doxycycline</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e477 class=n-a></a>Any drug that has already been<br class=br>approved for market use in humans and<br class=br>is now being used in a new formulation<br class=br>or for a new indication.</td></tr><tr><a name=d28479e487 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e489 class=n-a></a>Complex</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e492 class=n-a></a>Drug requires some<br class=br>phase I clinical trials to<br class=br>verify safety in humans</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e499 class=n-a></a>moxidectin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e502 class=n-a></a>Any drug that has already been<br class=br>approved for market use in humans and<br class=br>still requires clinical trials to verify safety<br class=br>in humans.</td></tr><tr><a name=d28479e512 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d28479e514 class=n-a></a><b>New chemical</b><br class=br><b>entity (NCE)</b></td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e521 class=n-a></a>Simple</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e524 class=n-a></a>Validated target/<br class=br>mechanism of action</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e529 class=n-a></a>primaquine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e532 class=n-a></a>Any chemically synthesized drug that is<br class=br>part of a well-established class of drugs<br class=br>or has a mechanism of action that has<br class=br>already been approved for market use<br class=br>in humans. It is not the first of its class to<br class=br>be approved.</td></tr><tr><a name=d28479e546 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e548 class=n-a></a>Simple - TB</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e551 class=n-a></a>Validated target/<br class=br>mechanism of action</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e556 class=n-a></a>Sutezolid (PNU-100480)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e559 class=n-a></a>Any candidate that meets criteria for a<br class=br>simple NCE and is developed for TB.</td></tr><tr><a name=d28479e565 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e567 class=n-a></a>Complex</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e570 class=n-a></a>Novel target/<br class=br>mechanism of action<br class=br>without understanding<br class=br>of disease<br class=br>pathogenesis</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e581 class=n-a></a>imatinib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e584 class=n-a></a>Any chemically synthesized drug that is<br class=br>first in its class as determined by having<br class=br>a novel target/mechanism of action<br class=br>regardless of the drug’s indication.</td></tr><tr><a name=d28479e595 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d28479e597 class=n-a></a><b>Biologics</b></td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e601 class=n-a></a>Simple</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e604 class=n-a></a>Validated target/<br class=br>mechanism of action</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e609 class=n-a></a>human monoclonal antibody<br class=br>m102.4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e614 class=n-a></a>Any drug that is synthesized from a<br class=br>living organism that is part of a well-<br class=br>established class of drugs or has a<br class=br>mechanism of action that has already<br class=br>been approved for market use in<br class=br>humans. It is not the first of its class to<br class=br>be approved.</td></tr><tr><a name=d28479e631 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e633 class=n-a></a>Simple - TB</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e636 class=n-a></a>Validated target/<br class=br>mechanism of action</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e641 class=n-a></a>CPZEN-45</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e644 class=n-a></a>Any candidate that meets criteria for a<br class=br>simple biologic and is developed for<br class=br>TB.</td></tr><tr><a name=d28479e652 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e654 class=n-a></a>Complex</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e657 class=n-a></a>Novel target/<br class=br>mechanism of action</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e662 class=n-a></a>polyclonal IgG antibodies</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e665 class=n-a></a>Any drug that is synthesized from a<br class=br>living organism that is first in its class as<br class=br>determined by having a novel target/<br class=br>mechanism of action regardless of the<br class=br>drug’s indication.</td></tr><tr><a name=d28479e677 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d28479e679 class=n-a></a><b>Vaccines</b></td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e683 class=n-a></a>Simple</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e686 class=n-a></a>Platform has been<br class=br>used to develop other<br class=br>vaccines.</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e693 class=n-a></a>Hep A, Hep B, polio, killed or<br class=br>live attenuated vaccines.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e698 class=n-a></a>Any vaccine platform that has been<br class=br>extensively researched and approved<br class=br>for use in the past. Conferral of immunity<br class=br>against disease-causing microorganism<br class=br>is expected as natural immunity to the<br class=br>pathogen is protective. Platform is likely<br class=br>to elicit robust protective response.</td></tr><tr><a name=d28479e715 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e717 class=n-a></a>Complex</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e720 class=n-a></a>Requires completely<br class=br>novel approach; no<br class=br>platform; no existing<br class=br>research</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e729 class=n-a></a>Pneumococcal conjugate<br class=br>vaccine, meningitis B, DNA<br class=br>vaccine or mRNA vaccines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e736 class=n-a></a>Any vaccine platform that requires<br class=br>a novel approach that has not been<br class=br>successfully approved for use in the<br class=br>past. Conferral of immunity against<br class=br>disease-causing microorganism is<br class=br>difficult to induce and maintain and<br class=br>natural immunity is not protective.<br class=br>Platform may elicit incomplete/<br class=br>insufficient immunity and require<br class=br>boosting over time.</td></tr><tr><a name=d28479e759 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e761 class=n-a></a>Unprecedented</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e764 class=n-a></a>Defined in the same<br class=br>way as complex<br class=br>vaccines, but with<br class=br>lower probabilities of<br class=br>success</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e775 class=n-a></a>HIV, TB, malaria vaccines</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e778 class=n-a></a>All vaccine candidates for HIV,<br class=br>TB, and malaria are classified as<br class=br>“unprecedented”; they have much<br class=br>higher attrition rates at phases II and III<br class=br>than other complex vaccines</td></tr><tr><a name=d28479e791 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e793 class=n-a></a><b>Other products</b></td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e797 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e799 class=n-a></a>This category refers to<br class=br>vector control products</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e804 class=n-a></a>Long-lasting insecticide-<br class=br>treated bed nets, new<br class=br>chemical pesticides</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e811 class=n-a></a>Chemical pesticides intended for global<br class=br>public health use that aim to control/kill<br class=br>vectors associated with transmitting<br class=br>poverty-related diseases; biological<br class=br>control interventions that aim to control/<br class=br>kill vectors associated with transmitting<br class=br>poverty-related diseases; veterinary<br class=br>vaccines designed to prevent animal-<br class=br>to-human transmission of neglected<br class=br>diseases.</td></tr><tr><a name=d28479e834 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d28479e836 class=n-a></a><b>Diagnostics</b></td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e840 class=n-a></a>Assay development</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e843 class=n-a></a>Development of a<br class=br>diagnostic assay</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e848 class=n-a></a>Lateral flow tests, qualitative/<br class=br>quantitative molecular tests</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e853 class=n-a></a>Any new diagnostic that represents<br class=br>menu extension on an existing platform<br class=br>with an assay targeting a neglected<br class=br>disease.</td></tr><tr><a name=d28479e863 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e865 class=n-a></a>Simple technical<br class=br>platform<br class=br>development</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e872 class=n-a></a>Development of a<br class=br>technical platform<br class=br>that enhances current<br class=br>technology</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e881 class=n-a></a>Ultrasensitive malaria rapid<br class=br>diagnostic test</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e886 class=n-a></a>Any new diagnostic that relies on a<br class=br>novel approach to sample processing or<br class=br>target detection.</td></tr></tbody></table></div><p class="" id=d28479e897>For each of the 14 different archetypes in P2I.v2, the model has assumptions on costs, attrition rates, and cycle time per phase. As described in detail in Terry <i>et al</i>, assumptions on development costs for each phase of product development for the archetypes included in the P2I.v1 model were initially based on an analysis of clinical trial costs from Parexel’s R&amp;D cost sourcebook<sup><a href="#ref-7">7</a></sup>. The assumptions on attrition rates and cycle times for each phase were initially based on the historical attrition rates and cycle times of more than 25,000 development candidates. All of the assumptions were further refined and validated based on (i) academic literature, (ii) industry publications and databases, and (iii) 133 stakeholder interviews with a wide variety of product development partnerships (PDPs), pharmaceutical companies, and major funders of global health R&amp;D<sup><a href="#ref-7">7</a></sup>. As described in detail in reference 6, additional sources of assumptions for the new archetypes in P2I.v2, such as vector control products and unprecedented vaccines, were the McKinsey Risk-Adjusted Portfolio Model and clinical trial data shared by the Bill &amp; Melinda Gates Foundation<sup><a href="#ref-6">6</a></sup>.</p><p class="" id=d28479e915>In order to use the model to analyse the pipeline of product candidates for poverty-related and neglected diseases, each candidate must first be classified into its archetype and phase, and then these candidates can be inputted into the model. There are two main model outputs. The first is “launches”; in this paper, the term launch refers to a candidate making it through phase III and thus being ready for the next steps, e.g. the regulatory and manufacturing steps. The second is the total costs to move all candidates through the pipeline from their current phase from now to 2031 (the model also gives a breakdown of these total costs into annual costs by year, from 2019 to 2031).</p><p class="" id=d28479e918>The model only includes candidates in advanced preclinical to phase III research, and thus the cost estimates are an under-estimate of the full costs of product development. In particular, the model excludes all costs related to basic research through lead optimization; chemistry, manufacturing, and controls; good manufacturing practice; manufacturing, build-up, and scale-up costs; regulatory or registration fees (post-phase III); and all post-market commitments (e.g., phase IV pharmacovigilance studies).</p></div><div class=section><a name=d28479e922 class=n-a></a><h3 class=section-title>(ii) Pipeline portfolio review</h3><p class="" id=d28479e927>We undertook <a target=xrefwindow href="https://www.pipeline.policycuresresearch.org/august2019" id=d28479e929>a global review of candidate products</a> for neglected diseases, Ebola and sexual &amp; reproductive health issues in order to capture a snapshot of the R&amp;D pipeline as of August 31, 2019 (“2019 review”); this followed a previously published review<sup><a href="#ref-6">6</a></sup> of the R&amp;D pipeline as of August 31, 2017 (“2017 review”).</p><p class="" id=d28479e937>The scope of candidate inclusion aligned with the <a target=xrefwindow href="https://www.policycuresresearch.org/g-finder" id=d28479e939>G-FINDER survey</a> on global funding for R&amp;D for neglected diseases, emerging infectious diseases and sexual &amp; reproductive health issues, conducted by Policy Cures Research. The G-FINDER scope is based on three key principles: that the disease or health issue disproportionately affects low- and middle-income countries; that there is a need for new products (i.e. there is no existing product, or improved or additional products are needed); and that there is a market failure (i.e. there is insufficient commercial market to attract private R&amp;D investment).</p><p class="" id=d28479e943>The scope of the G-FINDER project is reviewed annually in consultation with an expert Advisory Committee. As a result of these consultations, and following an initiative to survey the landscape of sexual and reproductive health R&amp;D funding, the disease scope used for the pipeline review in 2019 was wider than in 2017, with the addition of the following diseases: chlamydia, gonorrhea, hepatitis B, HPV-cervical cancer, human T-cell lymphotropic virus-1, herpes simplex-2, mycetoma, pre-eclampsia, post-partum hemorrhage and syphilis. Snakebite envenoming was added to the G-FINDER scope after the conclusion of the 2019 pipeline review and was therefore not included in the scope of this analysis. “Reproductive health”—which included both contraception and the prevention of sexually transmitted diseases through the use of multipurpose prevention technologies (MPTs) that prevent pregnancy and sexually transmitted infections—was included as a single health issue.</p><p class="" id=d28479e946>Accordingly, the R&amp;D pipeline review presented here comprises 45 individual disease or health issues and six multiple-disease groups (<i>Underlying data:</i> <a target=xrefwindow href="https://osf.io/nmvp6/" id=d28479e951>Data File 1</a> shows the full list of diseases included in the pipeline reviews for both 2017 and 2019).</p><p class="" id=d28479e956>The G-FINDER scope includes drugs, microbicides, biologics, vaccines, diagnostics, vector control products, devices and MPTs. Not all product types are included for every disease or health condition: the product category is excluded if a viable commercial market is thought to exist, and additional restrictions are applied to some disease and product categories if there is potential commercial (high-income country market) overlap. For example, the G-FINDER scope excludes dengue vaccines, and HIV/AIDS drugs are included only if they are label-extensions or reformulations specifically intended for developing country use (e.g., pediatric or slow-release formulations; fixed dose combinations; low-dose formulations for prophylaxis; long-acting injectables for treatment or prophylaxis). Medical devices (except for diagnostics and contraceptives), and general or supportive therapies (e.g., oral rehydration or nutritional supplements) are not included in the scope of G-FINDER and were therefore not included in the pipeline reviews. Due to changes in the G-FINDER scope between 2017 and 2019, as described above, two disease-specific product areas were included for the first time in 2019: vaccines for leprosy, and biologics for HIV.</p><p class="" id=d28479e959>The pipeline review included candidates at all stages of development, from discovery through to product registration. Drugs, vaccines, and reproductive health candidate products were classified in the following five development stages: discovery; pre-clinical studies; and clinical development (Phase I, Phase II and Phase III). Diagnostics and vector control products follow different product development and regulatory pathways, so these candidate products were classified under the following stages: concept and research; feasibility and planning; design and development; and clinical validation and launch readiness. Candidates were no longer considered to be part of the R&amp;D pipeline – and therefore were excluded from this analysis – once granted regulatory approval by a stringent regulatory authority, or if their development had been placed on hold indefinitely. Candidates in the discovery phase were also excluded, as only candidates undergoing advanced pre-clinical development up to Phase III are included in the P2I.v2 model.</p><p class="" id=d28479e962>Further details on the diseases and product areas within the scope of the pipeline analysis are provided in the <a target=xrefwindow href="https://www.policycuresresearch.org/r-and-d-needs-for-global-health" id=d28479e964>G-FINDER R&amp;D matrices and scope documents</a>.</p><p class="" id=d28479e968>We reviewed and cross-referenced all major sources of available data on the R&amp;D pipeline within the scope outlined above. Sources included: the <a target=xrefwindow href="https://gfinderdata.policycuresresearch.org/" id=d28479e970>G-FINDER R&amp;D funding database</a>; the <a target=xrefwindow href="https://www.who.int/immunization/research/development/Rainbow_tables/en/" id=d28479e973>World Health Organization “rainbow tables”</a>; publications of the <a target=xrefwindow href="https://www.who.int/immunization/research/en/" id=d28479e976>WHO Initiative for Vaccine Research (IVR)</a> which included background documents and meeting reports and presentations prepared for the WHO Product Development for Vaccines Advisory Committee (PDVAC) and Strategic Advisory Group of Experts (SAGE) on immunizations; reports of the <a target=xrefwindow href="https://www.who.int/vector-control/vcag/en/" id=d28479e979>WHO Vector Control Advisory Group (VCAG)</a> reports; WHO R&amp;D roadmaps; the <a target=xrefwindow href="https://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/" id=d28479e982>WHO vaccine pipeline tracker</a>; WHO prequalification lists; multiple Unitaid landscape and technical reports; multiple clinical trial portals including <a target=xrefwindow href="https://clinicaltrials.gov/" id=d28479e986>ClinicalTrials.gov</a>, the <a target=xrefwindow href="https://aidsinfo.nih.gov/clinical-trials" id=d28479e989>AIDS<i>info</i> clinical trial database</a>, the <a target=xrefwindow href="http://www.chictr.org.cn/searchprojen.aspx" id=d28479e995>Chinese Clinical Trial Registry</a>, the <a target=xrefwindow href="http://ctri.nic.in/Clinicaltrials/advancesearchmain.php" id=d28479e998>Clinical Trials Registry – India</a> and the <a target=xrefwindow href="http://apps.who.int/trialsearch/" id=d28479e1001>WHO International Clinical Trials Registry Platform</a>; disease-specific pipeline updates by the <a target=xrefwindow href="https://www.hvtn.org/en.html" id=d28479e1004>HIV Vaccines Trials Network</a> and the <a target=xrefwindow href="https://www.treatmentactiongroup.org/resources/pipeline-report/2019-pipeline-report/" id=d28479e1008>Treatment Action Group</a>; publicly available company and product development partnership R&amp;D portfolios; journal publications; conference and meeting proceedings; and university, government, and non-profit organization websites.</p><p class="" id=d28479e1012>Candidates were only included if an authoritative source could confirm they were in active development. The following sources were considered to be authoritative:</p><div class=list><a name=d28479e1015 class=n-a></a><ul style="list-style-type: none"><li><p id=d28479e1022><span class=label>▪ </span> the website of the candidate developer, if recently updated</p></li><li><p id=d28479e1031><span class=label>▪ </span> recent reports or other materials from international organizations such as WHO and Unitaid</p></li><li><p id=d28479e1040><span class=label>▪ </span> clinical trial portals</p></li><li><p id=d28479e1049><span class=label>▪ </span> correspondence with product developers</p></li><li><p id=d28479e1058><span class=label>▪ </span> correspondence with experts in the field, including FIND; the Innovative Vector Control Consortium (IVCC); the International AIDS Vaccine Initiative (IAVI); Netherlands Leprosy Relief; Program for Appropriate Technology in Health (PATH); the Sabin Vaccine Institute; and the US National Institute of Allergy and Infectious Diseases (NIAID).</p></li></ul></div></div><div class=section><a name=d28479e1064 class=n-a></a><h3 class=section-title>(iii) Classification of candidates into archetypes</h3><p class="" id=d28479e1069>In the pipeline portfolio review, we identified a total of 1160 product candidates for neglected diseases, Ebola and sexual &amp; reproductive health as of August 31, 2019. We excluded 406 of these from the model because (a) they were already marketed, or in a development phase that is excluded from the P2I.v2 model (n=230), (b) there was insufficient information about the candidate from an authoritative source to be able to confirm its development phase or classify it into an archetype (n=10), or (c) the candidate was no longer in development (n=166). After these exclusions, 754 candidates were included in the model.</p><p class="" id=d28479e1072>We then classified each of the included candidates into six primary archetypes: repurposed drugs, NCEs, vaccines, biologics, diagnostics, and ‘other products’ (which included only vector control products). Candidates classified as repurposed drugs, NCEs, or biologics were further classified as either simple or complex (with a further distinction for simple NCEs and simple biologics targeting TB); vaccine candidates were classified as either simple, complex, or unprecedented; and diagnostic candidates were classified as either assay development or simple platforms. This resulted in each candidate being assigned to one of the 14 unique archetypes outlined in <a href="#T1">Table 1</a>.</p><p class="" id=d28479e1078>Contraceptives, microbicides and MPTs were classified according to the constituent molecule (NCE, repurposed drug, or biologics). If there was more than one active drug ingredient in the MPT, the candidate was classified according to the most complicated component; we did not consider if the polymer or technology itself was innovative. TB drug candidates beyond Phase IIa were listed as regimens instead of individual compounds because TB treatment is regimen-based rather than monotherapy. Eight diagnostics candidates that were classified in the 2017 review as simple platforms were reclassified as assay development, reflecting the fact that ongoing activity was restricted to disease-specific assay development based on a previously validated proprietary diagnostic test technology.</p><p class="" id=d28479e1081>The evidence used to support the classification of candidates into archetypes came from a wide range of sources, including academic literature (both original research and review articles); relevant publicly available product databases such as <a target=xrefwindow href="https://drugs.ncats.io/" id=d28479e1083>NCATS Inxight: Drugs</a>; information from international clinical trials registries, including ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform; websites of PDPs; patent databases; and relevant reports and news releases from bilateral and multilateral funding agencies, companies, PDPs, other product developers, and non-government organizations. In assigning each candidate product to an archetype, we documented any relevant source material that guided the classification, such as a peer-reviewed research article on the candidate’s mechanism of action. Regimens were classified according to the complexity of the most complicated component.</p></div><div class=section><a name=d28479e1089 class=n-a></a><h3 class=section-title>(iv) Inputting the pipeline of candidates into the adapted P2I model</h3><p class="" id=d28479e1094>Following the pipeline portfolio review and classification of product candidates into their archetypes, the candidates that met our inclusion criteria were inputted into P2I.v2. For each disease and archetype, we entered the number of candidates that were in each phase of development at the time of our review. For the candidates classified as repurposed drugs, NCEs, biologics, vaccines, and “other products” (vector control products), the phases were preclinical, phase I, phase II, or phase III. For diagnostic candidates, the phases were concept and research, feasibility and planning, design and development, or clinical validation and launch readiness. The analysis was conducted in November 2019, and hence we selected 2019 as the start year for the modeling.</p><p class="" id=d28479e1097>Based on the previously established parameters for cost, attrition rate, and time per phase for each archetype, the model estimates the costs and outcomes of moving product candidates through the pipeline from their current phase. When a candidate is classified into a particular phase in the model, it is assumed that it is at the beginning of the phase, which means that the cost of moving that candidate through to the end of its current phase is included in the total estimated costs for any given product.</p><p class="" id=d28479e1100>We did not apply a discount rate to our cost estimates. Probability of success, length of phase, cost variables, and archetype were assumed to remain constant throughout the lifecycle of the model. Only candidates that met our inclusion criteria at the time of the pipeline portfolio review were included, meaning that the analysis did not include new candidates entering the pipeline over time.</p><p class="" id=d28479e1103>For this paper, we have chosen a conservative approach to presenting the launches—we have considered a launch to be a binary event, i.e., we have rounded down (in this case, 2.7 rounds down to 2 launches). However, in <i>Underlying data:</i> <a target=xrefwindow href="https://osf.io/2dz8v/" id=d28479e1108>Data File 2</a>, we also present the results without any rounding (e.g., in this example, 2.7 launches) and with rounding to the nearest integer (2.7 would round to 3). Both of these other approaches give less conservative estimates of the number of launches. Where rounding was used, it was only applied at the very end of the model. For example, for disease X, if there were 3 simple vaccine candidates at Phase II that led to 1.3 expected launches and 3 simple vaccine candidates at Phase III that led to 1.4 expected launches, we rounded the cumulative total (in this case 2.7).</p><p class="" id=d28479e1113>In this paper, we call the current pipeline of candidates the “2019 pipeline” (i.e. the pipeline of candidates as of August 31, 2019). We call the previously identified pipeline, published by Young et al, the “2017 pipeline” (i.e. the pipeline as of August 31, 2017)<sup><a href="#ref-6">6</a></sup>. As described below, we conducted two distinct analyses. First, we did an analysis to obtain a time trend—that is, we examined changes over time in the number of candidates in the pipeline, the estimated costs to move them through the pipeline, and the likely resulting launches. For this time trend analysis, we used the exact same scope of diseases—an “apples to apples” comparison (we call this the “direct comparison” between the 2017 and 2019 pipelines). We call the 2019 pipeline used for the direct comparison analysis the “2019 direct comparison pipeline.” Second, for the 2019 pipeline, we also used an expanded list of diseases. We call the pipeline used for the complete 2019 analysis the “complete 2019 pipeline.”</p><p class="" id=d28479e1120><b><i>The direct (“apples-to-apples”) comparison analysis between the 2017 and 2019 pipelines</i>.</b> The direct comparison analysis included product candidates in the 2019 pipeline that were identified using the <i>exact same</i> scope and search methodology used in 2017<sup><a href="#ref-6">6</a></sup>. As described in the Results section, we found a higher number of candidates in the 2019 direct comparison pipeline than in the 2017 pipeline. Since we used the same approach to identify candidates for both the 2017 and 2019 direct comparison pipelines, the higher number of overall candidates identified in 2019 was due to “true” changes in the pipeline since 2017. Despite the overall increase, when disaggregated by disease and by archetype the pipeline showed both increases and decreases in the numbers of candidate products across different diseases/archetypes. The product candidates included in the 2019 direct comparison pipeline belonged to the exact same 35 diseases and 5 multiple disease categories as those included in the 2017 pipeline analysis<sup><a href="#ref-6">6</a></sup>.</p><p class="" id=d28479e1138><b><i>The complete 2019 pipeline analysis</i>.</b> The complete 2019 pipeline analysis included all candidates from the pipeline portfolio review that met our inclusion criteria based on an expanded scope of diseases (45 diseases and 6 multiple disease categories). Again, as described in the Results section, we found a higher number of candidates in the complete 2019 pipeline than in the 2017 pipeline, but in this case the increase was partly due to the expansion of the disease scope, as well as true changes in the pipeline. Additionally, eight diagnostic candidate archetype classifications were changed between the 2019 direct comparison pipeline and the complete 2019 pipeline. These were existing candidates captured in the 2017 pipeline, and so their archetype classification was left unchanged in the direct comparison analysis to allow a true apples-to-apples comparison. This classification was updated for the complete pipeline analysis to reflect the fact that ongoing development activity for these candidates was now restricted to disease-specific assay development based on a previously validated proprietary diagnostic test technology.</p></div><div class=section><a name=d28479e1146 class=n-a></a><h3 class=section-title>(v) Estimating the costs of priority “missing” products</h3><p class="" id=d28479e1151>As described in the Results section below, the complete 2019 pipeline is unlikely to lead to launches of several critically needed technologies (e.g. a hepatitis C vaccine). To estimate the costs to develop products that are likely to be “missing” but are highly needed, we used the same methodology adopted by Young <i>et al</i>.<sup><a href="#ref-6">6</a></sup> Young <i>et al</i>. used the list of “important” or “game changing” diagnostics, drugs, and vaccines prioritized by the CIH, which was developed through expert consensus<sup><a href="#ref-1">1</a></sup>. We examined the overlap between the CIH’s list of needed products and those that our modeling suggested would still be missing by 2031 based on the complete 2019 pipeline. For each missing product, we used the P2I.v2 model in a retrospective manner to estimate the number of additional candidates that would be needed at preclinical phase—over and above the existing candidates—to lead to one expected launch of that product, and the associated additional cost.</p><p class="" id=d28479e1168>For example, we found 39 malaria vaccine candidates in the pipeline and the modeling suggested that these would result in 0.41 launches. Thus, to estimate the additional costs to reach one launch, we estimated the number of additional candidates needed at preclinical phase and the associated additional costs to achieve an additional 0.59 launches (in this case, an additional 144 candidates would be needed at preclinical phase to achieve 0.59 launches, at an additional cost of $3.3 billion).</p></div><div class=section><a name=d28479e1172 class=n-a></a><h3 class=section-title>(vi) Sensitivity analysis</h3><p class="" id=d28479e1177>For the sensitivity analysis we adopted a method detailed by Mestre-Ferrandiz <i>et al.</i> at the United Kingdom Office of Health Economics in their study “The R&amp;D Cost of a New Medicine”<sup><a href="#ref-8">8</a></sup>. Young <i>et al.</i> also used this method<sup><a href="#ref-6">6</a></sup>. Based on this methodology, we altered the model’s parameters for cost per phase and attrition per phase for each archetype by 10 percent higher and 10 percent lower. We also examined the impact of all possible combinations of these changes (e.g., 10% higher probability of success per phase and a 10% higher cost per phase, 10% higher probability of success per phase and a 10% lower cost per phase, etc.). We conducted this sensitivity analysis for moving current candidates through the pipeline both in our direct comparison analysis and our analysis of the complete 2019 pipeline. Additionally, we conducted this sensitivity analysis for the costs of developing priority “missing” products. Since the length of time is independent of the cost variables in P2I model, we did not conduct a sensitivity analysis varying the length of time per phase.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28479e1198>Results</h2><div class=section><a name=d28479e1201 class=n-a></a><h3 class=section-title>(i) Candidates identified by the 2017 and the direct comparison 2019 pipelines</h3><p class="" id=d28479e1206>For the direct comparison analysis (the “apples-to-apples” approach), we only included candidates that were identified using the same method and scope used in 2017, as described in sub-section (ii) above. Using these inclusion criteria, we identified 690 candidates in the 2019 direct comparison pipeline that met the inclusion criteria for being entered into the P2I.v2 tool, an increase of 152 candidates from 2017 (see <i>Underlying data:</i> <a target=xrefwindow href="https://osf.io/x27e4/" id=d28479e1211>Data File 3</a>).</p><p class="" id=d28479e1215><a href="#T2">Table 2</a> shows the change in the number of candidates from 2017 to 2019 due to changes in the pipeline. The largest increase was for diagnostics, an increase of 67 candidates from 2017 to 2019, followed by vaccines (increase of 48 candidates), biologics (increase of 19 candidates), and repurposed drugs (increase of 13 candidates). For NCEs, there was a reduction in the number of candidates (2 fewer candidates in 2019 than in 2017).</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Product candidates in the 2017 and 2019 direct comparison pipelines, categorized by archetype and complexity.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e1231 class=n-a></a><thead><a name=d28479e1233 class=n-a></a><tr><a name=d28479e1235 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e1237 class=n-a></a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e1239 class=n-a></a></th><th align=center colspan=2 rowspan=1 valign=top><a name=d28479e1241 class=n-a></a>Number of candidates</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e1244 class=n-a></a></th></tr><tr><a name=d28479e1247 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e1249 class=n-a></a>Archetype</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e1252 class=n-a></a>Complexity</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e1255 class=n-a></a>2017</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e1258 class=n-a></a>2019 Direct<br class=br>comparison pipeline</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e1263 class=n-a></a>Difference due to<br class=br>changes in the pipeline</th></tr></thead><tbody><a name=d28479e1270 class=n-a></a><tr><a name=d28479e1272 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1274 class=n-a></a>Vaccines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1277 class=n-a></a>Simple</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1280 class=n-a></a>87</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1283 class=n-a></a>86</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1286 class=n-a></a>-1</td></tr><tr><a name=d28479e1290 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1292 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1294 class=n-a></a>Complex</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1297 class=n-a></a>19</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1300 class=n-a></a>58</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1303 class=n-a></a>39</td></tr><tr><a name=d28479e1307 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1309 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1311 class=n-a></a>Unprecedented</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1314 class=n-a></a>102</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1317 class=n-a></a>112</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1320 class=n-a></a>10</td></tr><tr><a name=d28479e1324 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1326 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1328 class=n-a></a><b>Total vaccines</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1332 class=n-a></a><b>208</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1336 class=n-a></a><b>256</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1340 class=n-a></a><b>48</b></td></tr><tr><a name=d28479e1345 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1347 class=n-a></a>NCEs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1350 class=n-a></a>Simple</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1353 class=n-a></a>64</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1356 class=n-a></a>40</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1359 class=n-a></a>-24</td></tr><tr><a name=d28479e1364 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1366 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1368 class=n-a></a>Complex</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1371 class=n-a></a>44</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1374 class=n-a></a>66</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1377 class=n-a></a>22</td></tr><tr><a name=d28479e1381 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1383 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1385 class=n-a></a><b>Total NCEs</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1389 class=n-a></a><b>108</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1393 class=n-a></a><b>106</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1397 class=n-a></a><b>-2</b></td></tr><tr><a name=d28479e1402 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1404 class=n-a></a>Diagnostics</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1407 class=n-a></a>Assay development</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1410 class=n-a></a>58</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1413 class=n-a></a>131</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1416 class=n-a></a>73</td></tr><tr><a name=d28479e1420 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1422 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1424 class=n-a></a>Simple</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1427 class=n-a></a>43</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1430 class=n-a></a>37</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1433 class=n-a></a>-6</td></tr><tr><a name=d28479e1437 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1439 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1441 class=n-a></a><b>Total diagnostics</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1445 class=n-a></a><b>101</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1449 class=n-a></a><b>168</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1453 class=n-a></a><b>67</b></td></tr><tr><a name=d28479e1458 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1460 class=n-a></a>Repurposed drugs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1463 class=n-a></a>Simple</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1466 class=n-a></a>44</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1469 class=n-a></a>59</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1472 class=n-a></a>15</td></tr><tr><a name=d28479e1477 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1479 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1481 class=n-a></a>Complex</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1484 class=n-a></a>46</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1487 class=n-a></a>44</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1490 class=n-a></a>-2</td></tr><tr><a name=d28479e1494 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1496 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1498 class=n-a></a><b>Total repurposed drugs</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1502 class=n-a></a><b>90</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1506 class=n-a></a><b>103</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1510 class=n-a></a><b>13</b></td></tr><tr><a name=d28479e1515 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1517 class=n-a></a>Biologics</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1520 class=n-a></a>Simple</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1523 class=n-a></a>7</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1526 class=n-a></a>12</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1529 class=n-a></a>5</td></tr><tr><a name=d28479e1533 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1535 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1537 class=n-a></a>Complex</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1540 class=n-a></a>8</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1543 class=n-a></a>22</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1546 class=n-a></a>14</td></tr><tr><a name=d28479e1550 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1552 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1554 class=n-a></a><b>Total biologics</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1558 class=n-a></a><b>15</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1562 class=n-a></a><b>34</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1566 class=n-a></a><b>19</b></td></tr><tr><a name=d28479e1571 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1573 class=n-a></a>Other products</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1576 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1578 class=n-a></a>16</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1581 class=n-a></a>23</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1584 class=n-a></a>7</td></tr><tr><a name=d28479e1589 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1591 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1593 class=n-a></a><b>Total other products</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1597 class=n-a></a><b>16</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1601 class=n-a></a><b>23</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1605 class=n-a></a><b>7</b></td></tr><tr><a name=d28479e1610 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1612 class=n-a></a><b>Total</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1616 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1618 class=n-a></a><b>538</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1622 class=n-a></a><b>690</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e1626 class=n-a></a><b>152</b></td></tr></tbody></table></div><p class="" id=d28479e1634><a href="#T3">Table 3</a> compares candidates between the 2017 and 2019 direct comparison pipelines by disease and indicates the change in the number of candidates from 2017 to 2019 due to changes in the pipeline. The largest increase in the number of candidates was for Ebola (an increase of 62 candidates), followed by reproductive health (28), and TB (22). The largest decreases were for HIV/AIDS (a decrease of 10 candidates), schistosomiasis (7) and non-typhoid Salmonella (3).</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Product candidates in the 2017 and 2019 direct comparison pipelines, categorized by disease.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e1651 class=n-a></a><thead><a name=d28479e1653 class=n-a></a><tr><a name=d28479e1655 class=n-a></a><th align=center colspan=4 rowspan=1 valign=top><a name=d28479e1657 class=n-a></a>Number of candidates</th></tr><tr><a name=d28479e1661 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e1663 class=n-a></a>Disease</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e1666 class=n-a></a>2017</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e1669 class=n-a></a>2019 Direct<br class=br>comparison pipeline</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e1674 class=n-a></a>Difference due to<br class=br>changes in the pipeline</th></tr></thead><tbody><a name=d28479e1681 class=n-a></a><tr><a name=d28479e1683 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1685 class=n-a></a>Buruli ulcer</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1688 class=n-a></a>4</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1691 class=n-a></a>6</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1694 class=n-a></a>2</td></tr><tr><a name=d28479e1698 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1700 class=n-a></a>Chagas</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1703 class=n-a></a>18</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1706 class=n-a></a>16</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1709 class=n-a></a>-2</td></tr><tr><a name=d28479e1713 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1715 class=n-a></a>Cholera</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1718 class=n-a></a>3</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1721 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1724 class=n-a></a>-1</td></tr><tr><a name=d28479e1728 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1730 class=n-a></a>Cryptococcal meningitis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1733 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1736 class=n-a></a>3</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1739 class=n-a></a>2</td></tr><tr><a name=d28479e1743 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1745 class=n-a></a>Cryptosporidiasis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1748 class=n-a></a>0</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1751 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1754 class=n-a></a>1</td></tr><tr><a name=d28479e1759 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1761 class=n-a></a>Dengue</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1764 class=n-a></a>7</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1767 class=n-a></a>9</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1770 class=n-a></a>2</td></tr><tr><a name=d28479e1774 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1776 class=n-a></a>Ebola</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1779 class=n-a></a>20</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1782 class=n-a></a>82</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1785 class=n-a></a>62</td></tr><tr><a name=d28479e1789 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1791 class=n-a></a>Enterotoxigenic E.coli (ETEC)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1794 class=n-a></a>8</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1797 class=n-a></a>6</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1800 class=n-a></a>-2</td></tr><tr><a name=d28479e1804 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1806 class=n-a></a>Giardia</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1809 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1812 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1815 class=n-a></a>0</td></tr><tr><a name=d28479e1819 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1821 class=n-a></a>HAT (Sleeping sickness)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1824 class=n-a></a>6</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1827 class=n-a></a>4</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1830 class=n-a></a>-2</td></tr><tr><a name=d28479e1834 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1836 class=n-a></a>Hepatitis C</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1839 class=n-a></a>16</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1842 class=n-a></a>15</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1845 class=n-a></a>-1</td></tr><tr><a name=d28479e1850 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1852 class=n-a></a>HIV/AIDS</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1855 class=n-a></a>99</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1858 class=n-a></a>89</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1861 class=n-a></a>-10</td></tr><tr><a name=d28479e1865 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1867 class=n-a></a>Hookworm</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1870 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1873 class=n-a></a>3</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1876 class=n-a></a>1</td></tr><tr><a name=d28479e1880 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1882 class=n-a></a>Leishmaniasis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1885 class=n-a></a>14</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1888 class=n-a></a>19</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1891 class=n-a></a>5</td></tr><tr><a name=d28479e1895 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1897 class=n-a></a>Leprosy</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1900 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1903 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1906 class=n-a></a>0</td></tr><tr><a name=d28479e1910 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1912 class=n-a></a>Leptospirosis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1915 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1918 class=n-a></a>6</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1921 class=n-a></a>5</td></tr><tr><a name=d28479e1925 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1927 class=n-a></a>Lymphatic filariasis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1930 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1933 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1936 class=n-a></a>0</td></tr><tr><a name=d28479e1941 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1943 class=n-a></a>Malaria</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1946 class=n-a></a>109</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1949 class=n-a></a>127</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1952 class=n-a></a>18</td></tr><tr><a name=d28479e1956 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1958 class=n-a></a>Meningitis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1961 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1964 class=n-a></a>11</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1967 class=n-a></a>9</td></tr><tr><a name=d28479e1971 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1973 class=n-a></a>Multiple diarrhoeal<br class=br>diseases</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1978 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1981 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1984 class=n-a></a>1</td></tr><tr><a name=d28479e1988 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e1990 class=n-a></a>Multiple salmonella<br class=br>infections</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1995 class=n-a></a>0</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e1998 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2001 class=n-a></a>1</td></tr><tr><a name=d28479e2005 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2007 class=n-a></a>Multiple vector borne<br class=br>diseases</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2012 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2015 class=n-a></a>4</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2018 class=n-a></a>3</td></tr><tr><a name=d28479e2022 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2024 class=n-a></a>Non-typhoidal<br class=br>Salmonella (NTS)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2029 class=n-a></a>7</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2032 class=n-a></a>4</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2035 class=n-a></a>-3</td></tr><tr><a name=d28479e2040 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2042 class=n-a></a>Onchocerciasis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2045 class=n-a></a>4</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2048 class=n-a></a>6</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2051 class=n-a></a>2</td></tr><tr><a name=d28479e2055 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2057 class=n-a></a>Pneumonia</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2060 class=n-a></a>8</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2063 class=n-a></a>12</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2066 class=n-a></a>4</td></tr><tr><a name=d28479e2070 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2072 class=n-a></a>Reproductive health</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2075 class=n-a></a>59</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2078 class=n-a></a>87</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2081 class=n-a></a>28</td></tr><tr><a name=d28479e2085 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2087 class=n-a></a>Rheumatic fever</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2090 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2093 class=n-a></a>4</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2096 class=n-a></a>2</td></tr><tr><a name=d28479e2100 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2102 class=n-a></a>Rotavirus</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2105 class=n-a></a>5</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2108 class=n-a></a>11</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2111 class=n-a></a>6</td></tr><tr><a name=d28479e2115 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2117 class=n-a></a>Schistosomiasis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2120 class=n-a></a>16</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2123 class=n-a></a>9</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2126 class=n-a></a>-7</td></tr><tr><a name=d28479e2131 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2133 class=n-a></a>Shigellosis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2136 class=n-a></a>13</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2139 class=n-a></a>14</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2142 class=n-a></a>1</td></tr><tr><a name=d28479e2146 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2148 class=n-a></a>Trachoma</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2151 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2154 class=n-a></a>2</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2157 class=n-a></a>0</td></tr><tr><a name=d28479e2161 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2163 class=n-a></a>Trichuriasis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2166 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2169 class=n-a></a>1</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2172 class=n-a></a>0</td></tr><tr><a name=d28479e2176 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2178 class=n-a></a>Tuberculosis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2181 class=n-a></a>98</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2184 class=n-a></a>120</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2187 class=n-a></a>22</td></tr><tr><a name=d28479e2191 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2193 class=n-a></a>Typhoid &amp; paratyphoid</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2196 class=n-a></a>6</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2199 class=n-a></a>9</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2202 class=n-a></a>3</td></tr><tr><a name=d28479e2206 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2208 class=n-a></a><b>Total</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2212 class=n-a></a><b>538</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2216 class=n-a></a><b>690</b></td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e2220 class=n-a></a><b>152</b></td></tr></tbody></table></div></div><div class=section><a name=d28479e2229 class=n-a></a><h3 class=section-title>(ii) Candidates identified in the complete 2019 pipeline</h3><p class="" id=d28479e2234>The complete 2019 pipeline included a total of 754 product candidates that were identified in the pipeline portfolio review and met the inclusion criteria for inputting into the P2I.v2 model, representing an increase of 216 product candidates compared with the 2017 pipeline (see <i>Underlying data:</i> <a target=xrefwindow href="https://osf.io/x27e4/" id=d28479e2239>Data File 3</a>). <a href="#T4">Table 4</a> and <a href="#T5">Table 5</a> show the product candidates in the 2017 and the complete 2019 pipelines, broken down by archetype (<a href="#T4">Table 4</a>) or by disease (<a href="#T5">Table 5</a>). In both tables, the difference in the number of candidates between 2017 and 2019 is further broken down into “difference due to changes in the pipeline” and “difference due to changes in scope.”</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Product candidates in the 2017 and the complete 2019 pipelines categorized by archetype and complexity.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e2267 class=n-a></a><thead><a name=d28479e2269 class=n-a></a><tr><a name=d28479e2271 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e2273 class=n-a></a></th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2275 class=n-a></a></th><th align=center colspan=2 rowspan=1 valign=top><a name=d28479e2277 class=n-a></a>Number of candidates</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2280 class=n-a></a></th><th align=center colspan=2 rowspan=1 valign=top><a name=d28479e2282 class=n-a></a>Change due to</th></tr><tr><a name=d28479e2286 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2288 class=n-a></a>Archetype</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2291 class=n-a></a>Complexity</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2294 class=n-a></a>2017</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2297 class=n-a></a>Complete 2019<br class=br>pipeline</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2302 class=n-a></a>Difference</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2306 class=n-a></a>Pipeline<br class=br>expansion</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2311 class=n-a></a>Scope<br class=br>expansion</th></tr></thead><tbody><a name=d28479e2318 class=n-a></a><tr><a name=d28479e2320 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2322 class=n-a></a>Vaccines</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2325 class=n-a></a>simple</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2328 class=n-a></a>87</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2331 class=n-a></a>98</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2334 class=n-a></a>11</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2338 class=n-a></a>-1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2341 class=n-a></a>12</td></tr><tr><a name=d28479e2345 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2347 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2349 class=n-a></a>Complex</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2352 class=n-a></a>19</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2355 class=n-a></a>61</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2358 class=n-a></a>42</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2362 class=n-a></a>39</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2365 class=n-a></a>3</td></tr><tr><a name=d28479e2369 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2371 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2373 class=n-a></a>Unprecedented</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2376 class=n-a></a>102</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2379 class=n-a></a>112</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2382 class=n-a></a>10</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2386 class=n-a></a>10</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2389 class=n-a></a>0</td></tr><tr><a name=d28479e2393 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2395 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2397 class=n-a></a><b>Total vaccines</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2401 class=n-a></a><b>208</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2405 class=n-a></a><b>271</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2409 class=n-a></a><b>63</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2414 class=n-a></a><b>48</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2418 class=n-a></a><b>15</b></td></tr><tr><a name=d28479e2423 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2425 class=n-a></a>NCEs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2428 class=n-a></a>simple</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2431 class=n-a></a>64</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2434 class=n-a></a>49</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2437 class=n-a></a>-15</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2441 class=n-a></a>-24</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2444 class=n-a></a>9</td></tr><tr><a name=d28479e2449 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2451 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2453 class=n-a></a>Complex</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2456 class=n-a></a>44</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2459 class=n-a></a>71</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2462 class=n-a></a>27</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2466 class=n-a></a>22</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2469 class=n-a></a>5</td></tr><tr><a name=d28479e2473 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2475 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2477 class=n-a></a><b>Total NCEs</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2481 class=n-a></a><b>108</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2485 class=n-a></a><b>120</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2489 class=n-a></a><b>12</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2494 class=n-a></a><b>-2</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2498 class=n-a></a><b>14</b></td></tr><tr><a name=d28479e2503 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2505 class=n-a></a>Diagnostics</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2508 class=n-a></a>Assay<br class=br>development</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2513 class=n-a></a>58</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2516 class=n-a></a>149</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2519 class=n-a></a>91</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2523 class=n-a></a>81</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2526 class=n-a></a>10</td></tr><tr><a name=d28479e2530 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2532 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2534 class=n-a></a>simple</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2537 class=n-a></a>43</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2540 class=n-a></a>30</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2543 class=n-a></a>-13</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2547 class=n-a></a>-14</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2550 class=n-a></a>1</td></tr><tr><a name=d28479e2554 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2556 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2558 class=n-a></a><b>Total diagnostics</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2562 class=n-a></a><b>101</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2566 class=n-a></a><b>179</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2570 class=n-a></a><b>78</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2575 class=n-a></a><b>67</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2579 class=n-a></a><b>11</b></td></tr><tr><a name=d28479e2584 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2586 class=n-a></a>Repurposed<br class=br>drugs</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2591 class=n-a></a>simple</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2594 class=n-a></a>44</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2597 class=n-a></a>62</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2600 class=n-a></a>18</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2604 class=n-a></a>15</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2607 class=n-a></a>3</td></tr><tr><a name=d28479e2612 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2614 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2616 class=n-a></a>complex</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2619 class=n-a></a>46</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2622 class=n-a></a>49</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2625 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2629 class=n-a></a>-2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2632 class=n-a></a>5</td></tr><tr><a name=d28479e2636 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2638 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2640 class=n-a></a><b>Total</b><br class=br><b>repurposed</b><br class=br><b>drugs</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2650 class=n-a></a><b>90</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2654 class=n-a></a><b>111</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2658 class=n-a></a><b>21</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2663 class=n-a></a><b>13</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2667 class=n-a></a><b>8</b></td></tr><tr><a name=d28479e2672 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2674 class=n-a></a>Biologics</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2677 class=n-a></a>simple</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2680 class=n-a></a>7</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2683 class=n-a></a>12</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2686 class=n-a></a>5</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2690 class=n-a></a>5</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2693 class=n-a></a>0</td></tr><tr><a name=d28479e2697 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2699 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2701 class=n-a></a>complex</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2704 class=n-a></a>8</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2707 class=n-a></a>38</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2710 class=n-a></a>30</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2714 class=n-a></a>14</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2717 class=n-a></a>16</td></tr><tr><a name=d28479e2721 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2723 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2725 class=n-a></a><b>Total biologics</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2729 class=n-a></a><b>15</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2733 class=n-a></a><b>50</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2737 class=n-a></a><b>35</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2742 class=n-a></a><b>19</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2746 class=n-a></a><b>16</b></td></tr><tr><a name=d28479e2751 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2753 class=n-a></a>Other<br class=br>products</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2758 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2760 class=n-a></a>16</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2763 class=n-a></a>23</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2766 class=n-a></a>7</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2770 class=n-a></a>7</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2773 class=n-a></a>0</td></tr><tr><a name=d28479e2778 class=n-a></a><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2780 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2782 class=n-a></a><b>Total other</b><br class=br><b>products</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2789 class=n-a></a><b>16</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2793 class=n-a></a><b>23</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2797 class=n-a></a><b>7</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2802 class=n-a></a><b>7</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2806 class=n-a></a><b>0</b></td></tr><tr><a name=d28479e2811 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2813 class=n-a></a><b>Total</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2817 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2819 class=n-a></a><b>538</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2823 class=n-a></a><b>754</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2827 class=n-a></a><b>216</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2832 class=n-a></a><b>152</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2836 class=n-a></a><b>64</b></td></tr></tbody></table></div><a name=T5 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 5. Product candidates in the 2017 and the complete 2019 pipelines categorized by disease.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e2855 class=n-a></a><thead><a name=d28479e2857 class=n-a></a><tr><a name=d28479e2859 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e2861 class=n-a></a></th><th align=center colspan=2 rowspan=1 valign=top><a name=d28479e2863 class=n-a></a>Number of<br class=br>candidates</th><th align=center colspan=2 rowspan=1 valign=top><a name=d28479e2868 class=n-a></a>Changes due to</th></tr><tr><a name=d28479e2872 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e2874 class=n-a></a>Disease</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2877 class=n-a></a>2017</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2880 class=n-a></a>2019</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2883 class=n-a></a>Pipeline<br class=br>expansion</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e2888 class=n-a></a>Scope<br class=br>expansion</th></tr></thead><tbody><a name=d28479e2895 class=n-a></a><tr><a name=d28479e2897 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2899 class=n-a></a>Buruli ulcer</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2902 class=n-a></a>4</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2905 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2908 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2911 class=n-a></a>0</td></tr><tr><a name=d28479e2915 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2917 class=n-a></a>Chagas</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2920 class=n-a></a>18</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2923 class=n-a></a>16</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2926 class=n-a></a>-2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2929 class=n-a></a>0</td></tr><tr><a name=d28479e2933 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2935 class=n-a></a>Chlamydia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2938 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2941 class=n-a></a>5</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2944 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2947 class=n-a></a>5</td></tr><tr><a name=d28479e2951 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2953 class=n-a></a>Cholera</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2956 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2959 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2962 class=n-a></a>-1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2965 class=n-a></a>0</td></tr><tr><a name=d28479e2969 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2971 class=n-a></a>Cryptococcal meningitis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2974 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2977 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2980 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2983 class=n-a></a>0</td></tr><tr><a name=d28479e2988 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e2990 class=n-a></a>Cryptosporidiasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2993 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2996 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e2999 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3002 class=n-a></a>0</td></tr><tr><a name=d28479e3006 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3008 class=n-a></a>Dengue</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3011 class=n-a></a>7</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3014 class=n-a></a>9</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3017 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3020 class=n-a></a>0</td></tr><tr><a name=d28479e3024 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3026 class=n-a></a>Ebola</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3029 class=n-a></a>20</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3032 class=n-a></a>82</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3035 class=n-a></a>62</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3038 class=n-a></a>0</td></tr><tr><a name=d28479e3042 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3044 class=n-a></a>Enterotoxigenic E.coli (ETEC)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3047 class=n-a></a>8</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3050 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3053 class=n-a></a>-2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3056 class=n-a></a>0</td></tr><tr><a name=d28479e3060 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3062 class=n-a></a>Giardia</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3065 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3068 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3071 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3074 class=n-a></a>0</td></tr><tr><a name=d28479e3078 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3080 class=n-a></a>Gonorrhea</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3083 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3086 class=n-a></a>11</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3089 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3092 class=n-a></a>11</td></tr><tr><a name=d28479e3097 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3099 class=n-a></a>HAT (Sleeping sickness)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3102 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3105 class=n-a></a>4</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3108 class=n-a></a>-2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3111 class=n-a></a>0</td></tr><tr><a name=d28479e3115 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3117 class=n-a></a>Hepatitis B</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3120 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3123 class=n-a></a>8</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3126 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3129 class=n-a></a>8</td></tr><tr><a name=d28479e3133 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3135 class=n-a></a>Hepatitis C</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3138 class=n-a></a>16</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3141 class=n-a></a>15</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3144 class=n-a></a>-1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3147 class=n-a></a>0</td></tr><tr><a name=d28479e3151 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3153 class=n-a></a>Herpes simplex-2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3156 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3159 class=n-a></a>7</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3162 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3165 class=n-a></a>7</td></tr><tr><a name=d28479e3169 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3171 class=n-a></a>HIV/AIDS</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3174 class=n-a></a>99</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3177 class=n-a></a>105</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3180 class=n-a></a>-10</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3183 class=n-a></a>16</td></tr><tr><a name=d28479e3187 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3189 class=n-a></a>HPV- cervical cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3192 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3195 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3198 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3201 class=n-a></a>1</td></tr><tr><a name=d28479e3206 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3208 class=n-a></a>Hookworm</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3211 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3214 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3217 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3220 class=n-a></a>0</td></tr><tr><a name=d28479e3224 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3226 class=n-a></a>Leishmaniasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3229 class=n-a></a>14</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3232 class=n-a></a>19</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3235 class=n-a></a>5</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3238 class=n-a></a>0</td></tr><tr><a name=d28479e3242 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3244 class=n-a></a>Leprosy</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3247 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3250 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3253 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3256 class=n-a></a>1</td></tr><tr><a name=d28479e3260 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3262 class=n-a></a>Leptospirosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3265 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3268 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3271 class=n-a></a>5</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3274 class=n-a></a>0</td></tr><tr><a name=d28479e3278 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3280 class=n-a></a>Lymphatic filariasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3283 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3286 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3289 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3292 class=n-a></a>0</td></tr><tr><a name=d28479e3296 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3298 class=n-a></a>Malaria</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3301 class=n-a></a>109</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3304 class=n-a></a>127</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3307 class=n-a></a>18</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3310 class=n-a></a>0</td></tr><tr><a name=d28479e3315 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3317 class=n-a></a>Meningitis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3320 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3323 class=n-a></a>11</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3326 class=n-a></a>9</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3329 class=n-a></a>0</td></tr><tr><a name=d28479e3333 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3335 class=n-a></a>Multiple diarrhoeal diseases</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3338 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3341 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3344 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3347 class=n-a></a>0</td></tr><tr><a name=d28479e3351 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3353 class=n-a></a>Multiple diseases</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3356 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3359 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3362 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3365 class=n-a></a>1</td></tr><tr><a name=d28479e3369 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3371 class=n-a></a>Multiple salmonella infections</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3374 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3377 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3380 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3383 class=n-a></a>0</td></tr><tr><a name=d28479e3387 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3389 class=n-a></a>Multiple vector borne diseases</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3392 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3395 class=n-a></a>4</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3398 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3401 class=n-a></a>0</td></tr><tr><a name=d28479e3405 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3407 class=n-a></a>Mycetoma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3410 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3413 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3416 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3419 class=n-a></a>1</td></tr><tr><a name=d28479e3424 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3426 class=n-a></a>Non-typhoidal Salmonella<br class=br>(NTS)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3431 class=n-a></a>7</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3434 class=n-a></a>4</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3437 class=n-a></a>-3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3440 class=n-a></a>0</td></tr><tr><a name=d28479e3444 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3446 class=n-a></a>Onchocerciasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3449 class=n-a></a>4</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3452 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3455 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3458 class=n-a></a>0</td></tr><tr><a name=d28479e3462 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3464 class=n-a></a>Pneumonia</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3467 class=n-a></a>8</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3470 class=n-a></a>12</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3473 class=n-a></a>4</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3476 class=n-a></a>0</td></tr><tr><a name=d28479e3480 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3482 class=n-a></a>Reproductive health</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3485 class=n-a></a>59</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3488 class=n-a></a>100</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3491 class=n-a></a>28</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3494 class=n-a></a>13</td></tr><tr><a name=d28479e3498 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3500 class=n-a></a>Rheumatic fever</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3503 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3506 class=n-a></a>4</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3509 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3512 class=n-a></a>0</td></tr><tr><a name=d28479e3516 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3518 class=n-a></a>Rotavirus</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3521 class=n-a></a>5</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3524 class=n-a></a>11</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3527 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3530 class=n-a></a>0</td></tr><tr><a name=d28479e3535 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3537 class=n-a></a>Schistosomiasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3540 class=n-a></a>16</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3543 class=n-a></a>9</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3546 class=n-a></a>-7</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3549 class=n-a></a>0</td></tr><tr><a name=d28479e3553 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3555 class=n-a></a>Shigellosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3558 class=n-a></a>13</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3561 class=n-a></a>14</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3564 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3567 class=n-a></a>0</td></tr><tr><a name=d28479e3571 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3573 class=n-a></a>Trachoma</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3576 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3579 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3582 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3585 class=n-a></a>0</td></tr><tr><a name=d28479e3589 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3591 class=n-a></a>Trichuriasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3594 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3597 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3600 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3603 class=n-a></a>0</td></tr><tr><a name=d28479e3607 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3609 class=n-a></a>Tuberculosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3612 class=n-a></a>98</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3615 class=n-a></a>120</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3618 class=n-a></a>22</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3621 class=n-a></a>0</td></tr><tr><a name=d28479e3625 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3627 class=n-a></a>Typhoid &amp; paratyphoid</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3630 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3633 class=n-a></a>9</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3636 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3639 class=n-a></a>0</td></tr><tr><a name=d28479e3644 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3646 class=n-a></a><b>Total</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3650 class=n-a></a><b>538</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3654 class=n-a></a><b>754</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3658 class=n-a></a><b>152</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e3662 class=n-a></a><b>64</b></td></tr></tbody></table></div><p class="" id=d28479e3670>Of the 216 additions from 2017 to 2019, 152 candidates were added from a “true” change in the pipeline and 64 product candidates were added due to a scope expansion. Out of these 64 product candidates, 31 products were identified due to either including a new archetype in the scope or due to change in the inclusion criteria of existing archetypes (<a href="#T6">Table 6</a>). The remaining 33 candidates identified due to the scope expansion belong to new diseases included in the 2019 pipeline. These were 5 candidates for chlamydia, 11 candidates for gonorrhea, 8 candidates for hepatitis B, 7 candidates for herpes simplex-2, and one candidate each for human papilloma virus-cervical cancer and mycetoma. These candidates are included in <a href="#T4">Table 4</a> under scope expansion.</p><a name=T6 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 6. Additional candidates included in 2019 pipeline due to the expansion of the G-FINDER scope.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e3691 class=n-a></a><thead><a name=d28479e3693 class=n-a></a><tr><a name=d28479e3695 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e3697 class=n-a></a>Disease</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e3700 class=n-a></a>Archetype</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e3703 class=n-a></a>Number of candidates</th></tr></thead><tbody><a name=d28479e3708 class=n-a></a><tr><a name=d28479e3710 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3712 class=n-a></a><b>HIV/AIDS</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3716 class=n-a></a>Biologics</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3719 class=n-a></a>16</td></tr><tr><a name=d28479e3723 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3725 class=n-a></a><b>Reproductive health</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3729 class=n-a></a>New chemical entity</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3732 class=n-a></a>7</td></tr><tr><a name=d28479e3736 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3738 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3740 class=n-a></a>Repurposed drugs</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3743 class=n-a></a>6</td></tr><tr><a name=d28479e3747 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3749 class=n-a></a><b>Leprosy</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3753 class=n-a></a>Vaccine</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3756 class=n-a></a>1</td></tr><tr><a name=d28479e3760 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3762 class=n-a></a><b>Multi-disease</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3766 class=n-a></a>Diagnostic</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3769 class=n-a></a>1</td></tr><tr><a name=d28479e3774 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3776 class=n-a></a><b>Total</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3780 class=n-a></a></td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3782 class=n-a></a><b>31</b></td></tr></tbody></table></div><p class="" id=d28479e3790><a href="#T7">Table 7</a> summarizes the changes in classification for the eight diagnostic product candidates based on the updated information available in 2019.</p><a name=T7 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 7. Summary of the changes in classifications of eight diagnostic candidates.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e3806 class=n-a></a><thead><a name=d28479e3808 class=n-a></a><tr><a name=d28479e3810 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e3812 class=n-a></a>Disease</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e3815 class=n-a></a>Original classification<br class=br>(in the direct comparison pipeline)</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e3820 class=n-a></a>New classification<br class=br>(in the complete 2019 pipeline)</th><th align=center colspan=1 rowspan=1 valign=top><a name=d28479e3825 class=n-a></a>Number of candidates</th></tr></thead><tbody><a name=d28479e3830 class=n-a></a><tr><a name=d28479e3832 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3834 class=n-a></a>HIV/AIDS</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3837 class=n-a></a>Simple platform</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3840 class=n-a></a>Assay development</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3843 class=n-a></a>3</td></tr><tr><a name=d28479e3847 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3849 class=n-a></a>Tuberculosis</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3852 class=n-a></a>Simple platform</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3855 class=n-a></a>Assay development</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3858 class=n-a></a>2</td></tr><tr><a name=d28479e3862 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3864 class=n-a></a>Hepatitis C</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3867 class=n-a></a>Simple platform</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3870 class=n-a></a>Assay development</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3873 class=n-a></a>2</td></tr><tr><a name=d28479e3877 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3879 class=n-a></a>Malaria</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3882 class=n-a></a>Simple platform</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3885 class=n-a></a>Assay development</td><td align=center colspan=1 rowspan=1 valign=top><a name=d28479e3888 class=n-a></a>1</td></tr></tbody></table></div></div><div class=section><a name=d28479e3896 class=n-a></a><h3 class=section-title>(iii) Overview of expected product launches and costs</h3><p class="" id=d28479e3901>The 2019 direct comparison pipeline is expected to lead to 196 launches by the year 2031 at a total cost of $19.9 billion, and the complete 2019 pipeline is expected to lead to 207 launches by the year 2031 at a total cost of $21 billion (<a href="#T8">Table 8</a>) (see <i>Underlying data:</i> <a target=xrefwindow href="https://osf.io/ut4p5/" id=d28479e3909>Data File 4</a> for the 2019 direct comparison pipeline model and <a target=xrefwindow href="https://osf.io/7rhzy/" id=d28479e3912>Data File 5</a> and <a target=xrefwindow href="https://osf.io/tr3hy/" id=d28479e3915>Data File 6</a> for the complete 2019 pipeline models).</p><a name=T8 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 8. Summary of expected launches and costs to move candidates through 2017, direct comparison and complete pipelines of 2019.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e3930 class=n-a></a><thead><a name=d28479e3932 class=n-a></a><tr><a name=d28479e3934 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d28479e3936 class=n-a></a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e3938 class=n-a></a>2017 pipeline</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e3941 class=n-a></a>Direct comparison<br class=br>2019 pipeline</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e3946 class=n-a></a>Complete 2019<br class=br>pipeline</th></tr></thead><tbody><a name=d28479e3953 class=n-a></a><tr><a name=d28479e3955 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3957 class=n-a></a>Expected launches by 2031</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3960 class=n-a></a>128</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3963 class=n-a></a>196</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3966 class=n-a></a>207</td></tr><tr><a name=d28479e3970 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3972 class=n-a></a>Costs to move candidates through<br class=br>pipeline ($, millions)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3977 class=n-a></a>16,348.78</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3980 class=n-a></a>19,869.98</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e3983 class=n-a></a>21,027.18</td></tr></tbody></table></div></div><div class=section><a name=d28479e3991 class=n-a></a><h3 class=section-title>(iv) Comparison of expected launches from the 2017 pipeline versus the direct comparison 2019 pipeline</h3><p class="" id=d28479e3996>The direct comparison 2019 pipeline is expected to lead to 105 combined launches of products to control HIV/AIDS, TB, and malaria; in comparison, the 2017 pipeline was expected to lead to 85 combined launches for these three diseases (<a href="#f3">Figure 3</a>). For all other poverty-related and neglected diseases, the direct comparison 2019 pipeline is expected to lead to 91 launches compared to 43 launches from the 2017 pipeline. Among diseases included in the direct comparison analysis, the largest increase in the number of expected launches based on the 2017 versus direct comparison 2019 pipelines would be for Ebola: the 2017 pipeline was expected to lead to two launches, and the direct comparison 2019 pipeline is expected to lead to 20 launches. This increase reflects the significant growth in the number of Ebola pipeline candidates under active development at the time of the 2019 review compared to the 2017 review.</p><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/26491/f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure3.gif"><img alt="f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/26491/f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure3.gif"></a><div class=caption><h3>Figure 3. Number of expected launches for HIV/AIDS, TB, malaria and Ebola: 2017 versus the direct comparison 2019 pipelines.</h3></div></div><p class="" id=d28479e4016>A key finding of the direct comparison analysis is that the 2019 pipeline is expected to lead to launches of HIV and TB vaccines. In our previous study, based on the 2017 pipeline, launches of HIV and TB vaccines were <i>not</i> expected (i.e. there was a probability of launch of under 1.0 for each)<sup><a href="#ref-6">6</a></sup>. <a href="#T9">Table 9</a> summarizes the expected number of launches based on the 2017 and the direct comparison 2019 pipeline, broken down by disease. The difference in expected launches between the 2017 and the direct comparison 2019 pipelines are summarized under the fourth column, labeled “Expected launches: difference due to changes in the pipeline,” in <a href="#T9">Table 9</a>.</p><a name=T9 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 9. Number of expected launches from the 2017 versus the direct comparison 2019 pipelines.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e4043 class=n-a></a><thead><a name=d28479e4045 class=n-a></a><tr><a name=d28479e4047 class=n-a></a><th colspan=1 rowspan=1><a name=d28479e4049 class=n-a></a></th><th align=center colspan=2 rowspan=1 valign=top><a name=d28479e4051 class=n-a></a>Expected launches</th><th colspan=1 rowspan=1><a name=d28479e4054 class=n-a></a></th></tr><tr><a name=d28479e4057 class=n-a></a><th align=left colspan=1 rowspan=1 valign=middle><a name=d28479e4059 class=n-a></a>Disease</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e4062 class=n-a></a>2017</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e4065 class=n-a></a>2019 Direct<br class=br>comparison pipeline</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e4070 class=n-a></a>Difference due to<br class=br>changes in the pipeline</th></tr></thead><tbody><a name=d28479e4077 class=n-a></a><tr><a name=d28479e4079 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4081 class=n-a></a>Buruli ulcer</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4084 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4087 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4090 class=n-a></a>1</td></tr><tr><a name=d28479e4093 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4095 class=n-a></a>Chagas</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4098 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4101 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4104 class=n-a></a>0</td></tr><tr><a name=d28479e4107 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4109 class=n-a></a>Cholera</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4112 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4115 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4118 class=n-a></a>-1</td></tr><tr><a name=d28479e4121 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4123 class=n-a></a>Dengue</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4126 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4129 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4132 class=n-a></a>1</td></tr><tr><a name=d28479e4135 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4137 class=n-a></a>Ebola</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4140 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4143 class=n-a></a>20</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4146 class=n-a></a>18</td></tr><tr><a name=d28479e4150 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4152 class=n-a></a>Enterotoxigenic E.coli (ETEC)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4155 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4158 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4161 class=n-a></a>0</td></tr><tr><a name=d28479e4164 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4166 class=n-a></a>HAT (Sleeping sickness)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4169 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4172 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4175 class=n-a></a>1</td></tr><tr><a name=d28479e4178 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4180 class=n-a></a>Hepatitis C</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4183 class=n-a></a>8</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4186 class=n-a></a>11</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4189 class=n-a></a>3</td></tr><tr><a name=d28479e4192 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4194 class=n-a></a>HIV/AIDS</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4197 class=n-a></a>23</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4200 class=n-a></a>19</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4203 class=n-a></a>-4</td></tr><tr><a name=d28479e4206 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4208 class=n-a></a>Leishmaniasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4211 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4214 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4217 class=n-a></a>3</td></tr><tr><a name=d28479e4220 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4222 class=n-a></a>Leprosy</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4225 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4228 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4231 class=n-a></a>1</td></tr><tr><a name=d28479e4235 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4237 class=n-a></a>Leptospirosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4240 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4243 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4246 class=n-a></a>5</td></tr><tr><a name=d28479e4249 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4251 class=n-a></a>Lymphatic filariasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4254 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4257 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4260 class=n-a></a>1</td></tr><tr><a name=d28479e4263 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4265 class=n-a></a>Malaria</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4268 class=n-a></a>27</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4271 class=n-a></a>38</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4274 class=n-a></a>11</td></tr><tr><a name=d28479e4277 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4279 class=n-a></a>Meningitis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4282 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4285 class=n-a></a>5</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4288 class=n-a></a>5</td></tr><tr><a name=d28479e4291 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4293 class=n-a></a>Multiple vector borne diseases</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4296 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4299 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4302 class=n-a></a>1</td></tr><tr><a name=d28479e4305 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4307 class=n-a></a>Pneumonia</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4310 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4313 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4316 class=n-a></a>2</td></tr><tr><a name=d28479e4320 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4322 class=n-a></a>Reproductive health</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4325 class=n-a></a>8</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4328 class=n-a></a>14</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4331 class=n-a></a>6</td></tr><tr><a name=d28479e4334 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4336 class=n-a></a>Rotavirus</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4339 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4342 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4345 class=n-a></a>1</td></tr><tr><a name=d28479e4348 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4350 class=n-a></a>Schistosomiasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4353 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4356 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4359 class=n-a></a>-1</td></tr><tr><a name=d28479e4362 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4364 class=n-a></a>Shigellosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4367 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4370 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4373 class=n-a></a>0</td></tr><tr><a name=d28479e4376 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4378 class=n-a></a>Trachoma</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4381 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4384 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4387 class=n-a></a>1</td></tr><tr><a name=d28479e4390 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4392 class=n-a></a>Tuberculosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4395 class=n-a></a>35</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4398 class=n-a></a>48</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4401 class=n-a></a>13</td></tr><tr><a name=d28479e4405 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4407 class=n-a></a>Typhoid &amp; paratyphoid</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4410 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4413 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4416 class=n-a></a>0</td></tr><tr><a name=d28479e4419 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4421 class=n-a></a><b>Total</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4425 class=n-a></a><b>128</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4429 class=n-a></a><b>196</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4433 class=n-a></a><b>68</b></td></tr></tbody></table></div></div><div class=section><a name=d28479e4442 class=n-a></a><h3 class=section-title>(v) Expected launches based on the complete 2019 pipeline analysis</h3><p class="" id=d28479e4447>As shown in <a href="#T8">Table 8</a>, the complete 2019 pipeline is expected to lead to 207 launches by the year 2031 compared with 196 expected launches by the year 2031 from the direct comparison 2019 pipeline. The 11 additional launches from the complete 2019 pipeline analysis compared to the 2019 direct comparison pipeline are due to (a) the scope expansion (which led to 64 newly identified candidates, as summarized in <a href="#T5">Table 5</a> and <a href="#T6">Table 6</a>), and (b) the reclassification of eight diagnostics, as summarized in <a href="#T7">Table 7</a>. The reclassification of diagnostics increased the number of candidates classified as assay development for some diseases resulting in additional launches compared to the 2019 direct comparison pipeline. The expected launches resulting from the complete 2019 pipeline analysis, which had an expanded scope of diseases, include six additional expected launches for diseases not included in the 2017 pipeline review. These launches are one NCE for hepatitis B; three diagnostics for chlamydia; and two diagnostics for gonorrhea.</p><p class="" id=d28479e4462>The scope expansion also added an expected launch of one biologic for HIV/AIDS and one repurposed drug for reproductive health. The remaining three additional launches were all diagnostics—for hepatitis C, TB, and malaria—and these additions are related to the changes in classification for diagnostic candidates.</p><p class="" id=d28479e4465>The expected additional launches based on the complete 2019 pipeline analysis compared to the direct comparison 2019 pipeline are summarized under “Difference in expected launches due to: scope expansion” and “Difference in expected launches due to: classification changes” in <a href="#T10">Table 10</a>.</p><a name=T10 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 10. Expected launches by disease based on the 2017 and the complete 2019 pipelines.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e4482 class=n-a></a><thead><a name=d28479e4484 class=n-a></a><tr><a name=d28479e4486 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e4488 class=n-a></a></th><th align=center colspan=2 rowspan=1 valign=middle><a name=d28479e4490 class=n-a></a>Expected launches</th><th align=center colspan=3 rowspan=1 valign=middle><a name=d28479e4493 class=n-a></a>Difference in launches due to</th></tr><tr><a name=d28479e4497 class=n-a></a><th align=left colspan=1 rowspan=1 valign=middle><a name=d28479e4499 class=n-a></a>Disease</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e4502 class=n-a></a>2017</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e4505 class=n-a></a>Complete 2019<br class=br>pipeline</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e4510 class=n-a></a>Changes in<br class=br>the pipeline</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e4515 class=n-a></a>Scope<br class=br>expansion</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e4521 class=n-a></a>Classification<br class=br>changes</th></tr></thead><tbody><a name=d28479e4528 class=n-a></a><tr><a name=d28479e4530 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4532 class=n-a></a>Buruli Ulcer</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4535 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4538 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4541 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4544 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4547 class=n-a></a></td></tr><tr><a name=d28479e4550 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4552 class=n-a></a>Chagas</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4555 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4558 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4561 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4564 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4567 class=n-a></a></td></tr><tr><a name=d28479e4570 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4572 class=n-a></a>Chlamydia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4575 class=n-a></a>Not in<br class=br>scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4580 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4583 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4586 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4590 class=n-a></a></td></tr><tr><a name=d28479e4593 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4595 class=n-a></a>Cholera</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4598 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4601 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4604 class=n-a></a>-1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4607 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4610 class=n-a></a></td></tr><tr><a name=d28479e4613 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4615 class=n-a></a>Dengue</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4618 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4621 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4624 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4627 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4630 class=n-a></a></td></tr><tr><a name=d28479e4634 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4636 class=n-a></a>Ebola</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4639 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4642 class=n-a></a>20</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4645 class=n-a></a>18</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4648 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4651 class=n-a></a></td></tr><tr><a name=d28479e4654 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4656 class=n-a></a>Enterotoxigenic E.coli<br class=br>(ETEC)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4661 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4664 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4667 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4670 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4673 class=n-a></a></td></tr><tr><a name=d28479e4676 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4678 class=n-a></a>Gonorrhea</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4681 class=n-a></a>Not in<br class=br>scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4686 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4689 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4692 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4696 class=n-a></a></td></tr><tr><a name=d28479e4699 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4701 class=n-a></a>HAT (Sleeping sickness)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4704 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4707 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4710 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4713 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4716 class=n-a></a></td></tr><tr><a name=d28479e4719 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4721 class=n-a></a>Hepatitis B</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4724 class=n-a></a>Not in<br class=br>scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4729 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4732 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4735 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4739 class=n-a></a></td></tr><tr><a name=d28479e4742 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4744 class=n-a></a>Hepatitis C</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4747 class=n-a></a>8</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4750 class=n-a></a>12</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4753 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4756 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4759 class=n-a></a>1</td></tr><tr><a name=d28479e4764 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4766 class=n-a></a>HIV/AIDS</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4769 class=n-a></a>23</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4772 class=n-a></a>20</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4775 class=n-a></a>-4</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4778 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4782 class=n-a></a></td></tr><tr><a name=d28479e4785 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4787 class=n-a></a>Leishmaniasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4790 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4793 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4796 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4799 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4802 class=n-a></a></td></tr><tr><a name=d28479e4805 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4807 class=n-a></a>Leprosy</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4810 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4813 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4816 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4819 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4822 class=n-a></a></td></tr><tr><a name=d28479e4825 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4827 class=n-a></a>Leptospirosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4830 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4833 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4836 class=n-a></a>5</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4839 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4842 class=n-a></a></td></tr><tr><a name=d28479e4845 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4847 class=n-a></a>Lymphatic filariasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4850 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4853 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4856 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4859 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4862 class=n-a></a></td></tr><tr><a name=d28479e4865 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4867 class=n-a></a>Malaria</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4870 class=n-a></a>27</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4873 class=n-a></a>39</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4876 class=n-a></a>11</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4879 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4882 class=n-a></a>1</td></tr><tr><a name=d28479e4887 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4889 class=n-a></a>Meningitis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4892 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4895 class=n-a></a>5</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4898 class=n-a></a>5</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4901 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4904 class=n-a></a></td></tr><tr><a name=d28479e4907 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4909 class=n-a></a>Multiple vector borne<br class=br>diseases</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4914 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4917 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4920 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4923 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4926 class=n-a></a></td></tr><tr><a name=d28479e4929 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4931 class=n-a></a>Pneumonia</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4934 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4937 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4940 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4943 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4946 class=n-a></a></td></tr><tr><a name=d28479e4949 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4951 class=n-a></a>Reproductive health</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4954 class=n-a></a>8</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4957 class=n-a></a>15</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4960 class=n-a></a>6</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4963 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4967 class=n-a></a></td></tr><tr><a name=d28479e4970 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4972 class=n-a></a>Rotavirus</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4975 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4978 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4981 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4984 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4987 class=n-a></a></td></tr><tr><a name=d28479e4990 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e4992 class=n-a></a>Schistosomiasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4995 class=n-a></a>3</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e4998 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5001 class=n-a></a>-1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5004 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5007 class=n-a></a></td></tr><tr><a name=d28479e5011 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5013 class=n-a></a>Shigellosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5016 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5019 class=n-a></a>2</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5022 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5025 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5028 class=n-a></a></td></tr><tr><a name=d28479e5031 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5033 class=n-a></a>Trachoma</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5036 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5039 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5042 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5045 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5048 class=n-a></a></td></tr><tr><a name=d28479e5051 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5053 class=n-a></a>Tuberculosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5056 class=n-a></a>35</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5059 class=n-a></a>49</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5062 class=n-a></a>13</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5065 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5068 class=n-a></a>1</td></tr><tr><a name=d28479e5072 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5074 class=n-a></a>Typhoid &amp; paratyphoid</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5077 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5080 class=n-a></a>1</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5083 class=n-a></a>0</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5086 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5089 class=n-a></a></td></tr><tr><a name=d28479e5092 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5094 class=n-a></a><b>Total</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5098 class=n-a></a><b>128</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5102 class=n-a></a><b>207</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5106 class=n-a></a><b>68</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5110 class=n-a></a><b>8</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5115 class=n-a></a><b>3</b></td></tr></tbody></table></div></div><div class=section><a name=d28479e5124 class=n-a></a><h3 class=section-title>(vi) Estimated costs to move candidates through the pipeline based on the 2017 and the direct comparison 2019 pipelines</h3><p class="" id=d28479e5129>It would cost a total of $19.9 billion to move the candidates in the direct comparison 2019 pipeline through to launch, compared with $16.3 billion to move candidates in the 2017 pipeline to launch, an increase of $3.5 billion from 2017 to 2019. The largest cost increase for any single disease category is for Ebola: it would cost an estimated $1.2 billion to move candidates in the 2017 pipeline to launch, compared with $2.8 billion to move candidates from the 2019 pipeline to launch, an increase of $1.7 billion. Comparing the direct comparison 2019 pipeline against the 2017 pipeline as a baseline, the cost to move candidates through the pipeline to launch increased by $238 million and $133.4 million for TB and malaria, respectively, while the cost to move candidates through the pipeline fell by $66.3 million for HIV/AIDS. <a href="#f4">Figure 4</a> compares the costs of moving candidates for HIV/AIDS, TB, Ebola, and malaria through the pipeline to launch based on the 2017 versus the direct comparison 2019 pipelines. <a href="#T11">Table 11</a> compares the costs to move candidates through the pipeline based on the 2017 and direct comparison 2019, disaggregated by disease (the cost differences are summarized under the column “Cost difference due to changes in the pipeline”). </p><a name=f4 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/26491/f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure4.gif"><img alt="f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/26491/f99f0e2b-b9ee-4f4d-9cd3-c86ea7f626b6_figure4.gif"></a><div class=caption><h3>Figure 4. Costs from the direct comparison analysis of moving candidates for HIV/AIDS, TB, Ebola, and malaria to launch.</h3></div></div><a name=T11 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 11. Cost to move candidates to launch by disease for the 2017 and 2019 direct comparison pipelines.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e5163 class=n-a></a><thead><a name=d28479e5165 class=n-a></a><tr><a name=d28479e5167 class=n-a></a><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e5169 class=n-a></a>Disease</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e5172 class=n-a></a>2017 ($,<br class=br>million)</th><th align=center colspan=1 rowspan=1 valign=middle><a name=d28479e5177 class=n-a></a>2019 pipeline for the<br class=br>direct comparison<br class=br>analysis ($, million)</th><th align=left colspan=1 rowspan=1 valign=middle><a name=d28479e5184 class=n-a></a>Difference due to pipeline<br class=br>expansion ($, million)</th></tr></thead><tbody><a name=d28479e5191 class=n-a></a><tr><a name=d28479e5193 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5194 class=n-a></a>Buruli ulcer</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5197 class=n-a></a>51.34</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5200 class=n-a></a>65.18</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5203 class=n-a></a>13.84</td></tr><tr><a name=d28479e5206 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5207 class=n-a></a>Chagas'</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5210 class=n-a></a>681.25</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5213 class=n-a></a>433.92</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5216 class=n-a></a>-247.33</td></tr><tr><a name=d28479e5219 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5220 class=n-a></a>Cholera</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5223 class=n-a></a>324.88</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5226 class=n-a></a>219.09</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5229 class=n-a></a>-105.80</td></tr><tr><a name=d28479e5232 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5233 class=n-a></a>Cryptococcal meningitis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5236 class=n-a></a>18.33</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5239 class=n-a></a>42.61</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5242 class=n-a></a>24.28</td></tr><tr><a name=d28479e5245 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5246 class=n-a></a>Cryptosporidiosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5249 class=n-a></a>0.00</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5252 class=n-a></a>18.33</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5255 class=n-a></a>18.33</td></tr><tr><a name=d28479e5259 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5260 class=n-a></a>Dengue</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5263 class=n-a></a>82.29</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5266 class=n-a></a>113.64</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5269 class=n-a></a>31.35</td></tr><tr><a name=d28479e5272 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5273 class=n-a></a>Ebola</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5276 class=n-a></a>1153.63</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5279 class=n-a></a>2831.53</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5282 class=n-a></a>1677.91</td></tr><tr><a name=d28479e5285 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5286 class=n-a></a>Enterotoxigenic <i>E.coli</i> (ETEC)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5292 class=n-a></a>538.73</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5295 class=n-a></a>421.54</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5298 class=n-a></a>-117.20</td></tr><tr><a name=d28479e5301 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5302 class=n-a></a>Giardia</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5305 class=n-a></a>54.30</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5308 class=n-a></a>54.24</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5311 class=n-a></a>-0.05</td></tr><tr><a name=d28479e5314 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5315 class=n-a></a>HAT (Sleeping sickness)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5318 class=n-a></a>74.57</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5321 class=n-a></a>31.07</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5324 class=n-a></a>-43.50</td></tr><tr><a name=d28479e5327 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5328 class=n-a></a>Hepatitis C</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5331 class=n-a></a>540.77</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5334 class=n-a></a>385.81</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5337 class=n-a></a>-154.96</td></tr><tr><a name=d28479e5341 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5342 class=n-a></a>HIV/AIDS</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5345 class=n-a></a>2307.81</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5348 class=n-a></a>2241.52</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5351 class=n-a></a>-66.30</td></tr><tr><a name=d28479e5354 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5355 class=n-a></a>Hookworm</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5358 class=n-a></a>147.95</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5361 class=n-a></a>197.18</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5364 class=n-a></a>49.24</td></tr><tr><a name=d28479e5367 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5368 class=n-a></a>Leishmaniasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5371 class=n-a></a>456.19</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5374 class=n-a></a>396.74</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5377 class=n-a></a>-59.45</td></tr><tr><a name=d28479e5380 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5381 class=n-a></a>Leprosy</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5384 class=n-a></a>18.20</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5387 class=n-a></a>17.39</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5390 class=n-a></a>-0.81</td></tr><tr><a name=d28479e5393 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5394 class=n-a></a>Leptospirosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5397 class=n-a></a>5.50</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5400 class=n-a></a>21.00</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5403 class=n-a></a>15.50</td></tr><tr><a name=d28479e5406 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5407 class=n-a></a>Lymphatic filariasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5410 class=n-a></a>18.29</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5413 class=n-a></a>7.00</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5416 class=n-a></a>-11.29</td></tr><tr><a name=d28479e5420 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5421 class=n-a></a>Malaria</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5424 class=n-a></a>2239.72</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5427 class=n-a></a>2373.16</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5430 class=n-a></a>133.45</td></tr><tr><a name=d28479e5433 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5434 class=n-a></a>Meningitis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5437 class=n-a></a>91.32</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5440 class=n-a></a>947.94</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5443 class=n-a></a>856.62</td></tr><tr><a name=d28479e5446 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5447 class=n-a></a>Multiple diarrhoeal diseases</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5450 class=n-a></a>13.61</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5453 class=n-a></a>61.02</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5456 class=n-a></a>47.40</td></tr><tr><a name=d28479e5459 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5460 class=n-a></a>Multiple salmonella infections</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5463 class=n-a></a>0.00</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5466 class=n-a></a>37.05</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5469 class=n-a></a>37.05</td></tr><tr><a name=d28479e5472 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5473 class=n-a></a>Multiple vector borne diseases</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5476 class=n-a></a>73.97</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5479 class=n-a></a>91.95</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5482 class=n-a></a>17.98</td></tr><tr><a name=d28479e5485 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5486 class=n-a></a>Non-typhoidal Salmonella<br class=br>(NTS)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5491 class=n-a></a>289.63</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5494 class=n-a></a>141.66</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5497 class=n-a></a>-147.97</td></tr><tr><a name=d28479e5501 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5502 class=n-a></a>Onchocerciasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5505 class=n-a></a>104.45</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5508 class=n-a></a>142.33</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5511 class=n-a></a>37.89</td></tr><tr><a name=d28479e5514 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5515 class=n-a></a>Pneumonia</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5518 class=n-a></a>644.20</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5521 class=n-a></a>1249.16</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5524 class=n-a></a>604.95</td></tr><tr><a name=d28479e5527 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5528 class=n-a></a>Reproductive health</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5531 class=n-a></a>908.55</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5534 class=n-a></a>1394.05</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5537 class=n-a></a>485.50</td></tr><tr><a name=d28479e5540 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5541 class=n-a></a>Rheumatic fever</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5544 class=n-a></a>111.00</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5547 class=n-a></a>222.03</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5550 class=n-a></a>111.02</td></tr><tr><a name=d28479e5553 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5554 class=n-a></a>Rotavirus</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5557 class=n-a></a>618.55</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5560 class=n-a></a>976.35</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5563 class=n-a></a>357.80</td></tr><tr><a name=d28479e5566 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5567 class=n-a></a>Schistosomiasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5570 class=n-a></a>830.37</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5573 class=n-a></a>407.38</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5576 class=n-a></a>-422.98</td></tr><tr><a name=d28479e5580 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5581 class=n-a></a>Shigellosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5584 class=n-a></a>855.13</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5587 class=n-a></a>824.27</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5590 class=n-a></a>-30.86</td></tr><tr><a name=d28479e5593 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5594 class=n-a></a>Trachoma</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5597 class=n-a></a>74.06</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5600 class=n-a></a>40.55</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5603 class=n-a></a>-33.51</td></tr><tr><a name=d28479e5606 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5607 class=n-a></a>Trichuriasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5610 class=n-a></a>17.60</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5613 class=n-a></a>17.58</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5616 class=n-a></a>-0.02</td></tr><tr><a name=d28479e5619 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5620 class=n-a></a>Tuberculosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5623 class=n-a></a>2569.48</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5626 class=n-a></a>2807.52</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5629 class=n-a></a>238.04</td></tr><tr><a name=d28479e5632 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5633 class=n-a></a>Typhoid &amp; paratyphoid</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5636 class=n-a></a>433.10</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5639 class=n-a></a>638.20</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5642 class=n-a></a>205.09</td></tr><tr><a name=d28479e5645 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5646 class=n-a></a><b>TOTAL</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5650 class=n-a></a><b>16348.78</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5654 class=n-a></a><b>19869.98</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5658 class=n-a></a><b>3521.19</b></td></tr></tbody></table></div></div><div class=section><a name=d28479e5666 class=n-a></a><h3 class=section-title>(vii) Costs to move candidates through the pipeline based on the complete 2019 pipeline</h3><p class="" id=d28479e5671>Compared to the direct comparison 2019 pipeline, an additional $1.2 billion is required to move candidates in the complete 2019 pipeline through the pipeline to launch (in the narrative part of this section, the individual costs do not always add up to the totals mentioned due to rounding; <a href="#T12">Table 12</a> gives the individual costs). This $1.2 billion increase in cost is due to the inclusion of additional product candidates as a result of the scope expansion. The largest increase in cost was for HIV/AIDS: it would cost an estimated $2,241.5 million to move candidates in the direct comparison 2019 pipeline through to launch, compared with $2,661.9 million to move candidates in the complete 2019 pipeline to launch, an increase of $420.4 million. This increase is explained by the addition of 16 biologic candidates for HIV/AIDS control in the complete 2019 pipeline compared with the direct comparison 2019 pipeline. For reproductive health, it would cost an estimated $1,394.1 million to move candidates in the direct comparison 2019 pipeline through to launch, compared with $1,579.9 million to move candidates in the complete 2019 pipeline to launch, an increase of $185.9 million. This increase is explained by the addition of 13 candidates for reproductive health in the complete 2019 pipeline compared with the direct comparison 2019 pipeline.</p><a name=T12 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 12. Cost to move candidates to launch by disease for the 2017 and complete 2019 pipelines.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e5688 class=n-a></a><thead><a name=d28479e5690 class=n-a></a><tr><a name=d28479e5692 class=n-a></a><th align=left colspan=1 rowspan=1 valign=bottom><a name=d28479e5694 class=n-a></a></th><th align=center colspan=2 rowspan=1 valign=bottom><a name=d28479e5696 class=n-a></a>Cost ($, million)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e5699 class=n-a></a></th><th align=center colspan=3 rowspan=1 valign=bottom><a name=d28479e5701 class=n-a></a>Cost difference due to</th></tr><tr><a name=d28479e5705 class=n-a></a><th align=left colspan=1 rowspan=1 valign=bottom><a name=d28479e5707 class=n-a></a>Disease</th><th align=left colspan=1 rowspan=1 valign=bottom><a name=d28479e5710 class=n-a></a>2017</th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d28479e5713 class=n-a></a>Complete<br class=br>2019 pipeline</th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d28479e5718 class=n-a></a>Difference<br class=br>($, million)</th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d28479e5723 class=n-a></a>Changes in<br class=br>the pipeline<br class=br>($, million)</th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d28479e5731 class=n-a></a>Scope<br class=br>expansion<br class=br>($, million)</th><th align=center colspan=1 rowspan=1 valign=bottom><a name=d28479e5738 class=n-a></a>Classification Changes<br class=br>($, million)</th></tr></thead><tbody><a name=d28479e5745 class=n-a></a><tr><a name=d28479e5747 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5749 class=n-a></a>Buruli ulcer</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5752 class=n-a></a>51.34</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5755 class=n-a></a>65.18</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5758 class=n-a></a>13.84</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5761 class=n-a></a>13.84</td><td align=left colspan=1 rowspan=1><a name=d28479e5765 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e5767 class=n-a></a></td></tr><tr><a name=d28479e5770 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5772 class=n-a></a>Chagas'</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5775 class=n-a></a>681.25</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5778 class=n-a></a>433.92</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5781 class=n-a></a>-247.33</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5784 class=n-a></a>-247.33</td><td align=left colspan=1 rowspan=1><a name=d28479e5788 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e5790 class=n-a></a></td></tr><tr><a name=d28479e5793 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5795 class=n-a></a>Cholera</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5798 class=n-a></a>324.88</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5801 class=n-a></a>219.09</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5804 class=n-a></a>-105.80</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5807 class=n-a></a>-105.80</td><td align=left colspan=1 rowspan=1><a name=d28479e5811 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e5813 class=n-a></a></td></tr><tr><a name=d28479e5816 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5818 class=n-a></a>Chlamydia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5821 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5824 class=n-a></a>27.02</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5827 class=n-a></a>27.02</td><td align=left colspan=1 rowspan=1><a name=d28479e5830 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5833 class=n-a></a>27.02</td><td align=left colspan=1 rowspan=1><a name=d28479e5836 class=n-a></a></td></tr><tr><a name=d28479e5839 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5841 class=n-a></a>Cryptococcal meningitis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5844 class=n-a></a>18.33</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5847 class=n-a></a>42.61</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5850 class=n-a></a>24.28</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5853 class=n-a></a>24.28</td><td align=left colspan=1 rowspan=1><a name=d28479e5857 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e5859 class=n-a></a></td></tr><tr><a name=d28479e5863 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5865 class=n-a></a>Cryptosporidiosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5868 class=n-a></a>0.00</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5871 class=n-a></a>18.33</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5874 class=n-a></a>18.33</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5877 class=n-a></a>18.33</td><td align=left colspan=1 rowspan=1><a name=d28479e5881 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e5883 class=n-a></a></td></tr><tr><a name=d28479e5886 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5888 class=n-a></a>Dengue</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5891 class=n-a></a>82.29</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5894 class=n-a></a>113.64</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5897 class=n-a></a>31.35</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5900 class=n-a></a>31.35</td><td align=left colspan=1 rowspan=1><a name=d28479e5904 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e5906 class=n-a></a></td></tr><tr><a name=d28479e5909 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5911 class=n-a></a>Ebola</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5914 class=n-a></a>1153.63</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5917 class=n-a></a>2831.53</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5920 class=n-a></a>1677.91</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5923 class=n-a></a>1677.91</td><td align=left colspan=1 rowspan=1><a name=d28479e5927 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e5929 class=n-a></a></td></tr><tr><a name=d28479e5932 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5934 class=n-a></a>Enterotoxigenic E.coli<br class=br>(ETEC)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5939 class=n-a></a>538.73</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5942 class=n-a></a>421.54</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5945 class=n-a></a>-117.20</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5948 class=n-a></a>-117.20</td><td align=left colspan=1 rowspan=1><a name=d28479e5952 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e5954 class=n-a></a></td></tr><tr><a name=d28479e5957 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5959 class=n-a></a>Giardia</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5962 class=n-a></a>54.30</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5965 class=n-a></a>54.24</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5968 class=n-a></a>-0.05</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5971 class=n-a></a>-0.05</td><td align=left colspan=1 rowspan=1><a name=d28479e5975 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e5977 class=n-a></a></td></tr><tr><a name=d28479e5980 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5982 class=n-a></a>Gonorrhea</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e5985 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5988 class=n-a></a>280.96</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5991 class=n-a></a>280.96</td><td align=left colspan=1 rowspan=1><a name=d28479e5994 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e5997 class=n-a></a>280.96</td><td align=left colspan=1 rowspan=1><a name=d28479e6000 class=n-a></a></td></tr><tr><a name=d28479e6004 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6006 class=n-a></a>HAT (Sleeping sickness)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6009 class=n-a></a>74.57</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6012 class=n-a></a>31.07</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6015 class=n-a></a>-43.50</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6018 class=n-a></a>-43.50</td><td align=left colspan=1 rowspan=1><a name=d28479e6022 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6024 class=n-a></a></td></tr><tr><a name=d28479e6027 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6029 class=n-a></a>Hepatitis B</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6032 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6035 class=n-a></a>122.26</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6038 class=n-a></a>122.26</td><td align=left colspan=1 rowspan=1><a name=d28479e6041 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6044 class=n-a></a>122.26</td><td align=left colspan=1 rowspan=1><a name=d28479e6047 class=n-a></a></td></tr><tr><a name=d28479e6050 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6052 class=n-a></a>Hepatitis C</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6055 class=n-a></a>540.77</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6058 class=n-a></a>191.76</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6061 class=n-a></a>-349.01</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6064 class=n-a></a>-154.96</td><td align=left colspan=1 rowspan=1><a name=d28479e6068 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6070 class=n-a></a>-194.05</td></tr><tr><a name=d28479e6074 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6076 class=n-a></a>Herpes Simplex-2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6079 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6082 class=n-a></a>416.58</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6085 class=n-a></a>416.58</td><td align=left colspan=1 rowspan=1><a name=d28479e6088 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6091 class=n-a></a>416.58</td><td align=left colspan=1 rowspan=1><a name=d28479e6094 class=n-a></a></td></tr><tr><a name=d28479e6097 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6099 class=n-a></a>HIV/AIDS</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6102 class=n-a></a>2307.81</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6105 class=n-a></a>2661.89</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6108 class=n-a></a>354.07</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6111 class=n-a></a>-66.30</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6115 class=n-a></a>683.30</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6118 class=n-a></a>-262.93</td></tr><tr><a name=d28479e6122 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6124 class=n-a></a>Hookworm</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6127 class=n-a></a>147.95</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6130 class=n-a></a>197.18</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6133 class=n-a></a>49.24</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6136 class=n-a></a>49.24</td><td align=left colspan=1 rowspan=1><a name=d28479e6140 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6142 class=n-a></a></td></tr><tr><a name=d28479e6146 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6148 class=n-a></a>HPV-cervical cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6151 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6154 class=n-a></a>5.40</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6157 class=n-a></a>5.40</td><td align=left colspan=1 rowspan=1><a name=d28479e6160 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6163 class=n-a></a>5.40</td><td align=left colspan=1 rowspan=1><a name=d28479e6166 class=n-a></a></td></tr><tr><a name=d28479e6169 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6171 class=n-a></a>Leishmaniasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6174 class=n-a></a>456.19</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6177 class=n-a></a>396.74</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6180 class=n-a></a>-59.45</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6183 class=n-a></a>-59.45</td><td align=left colspan=1 rowspan=1><a name=d28479e6187 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6189 class=n-a></a></td></tr><tr><a name=d28479e6192 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6194 class=n-a></a>Leprosy</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6197 class=n-a></a>18.20</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6200 class=n-a></a>80.30</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6203 class=n-a></a>62.10</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6206 class=n-a></a>-0.81</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6210 class=n-a></a>62.91</td><td align=left colspan=1 rowspan=1><a name=d28479e6213 class=n-a></a></td></tr><tr><a name=d28479e6216 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6218 class=n-a></a>Leptospirosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6221 class=n-a></a>5.50</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6224 class=n-a></a>21.00</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6227 class=n-a></a>15.50</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6230 class=n-a></a>15.50</td><td align=left colspan=1 rowspan=1><a name=d28479e6234 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6236 class=n-a></a></td></tr><tr><a name=d28479e6239 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6241 class=n-a></a>Lymphatic filariasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6244 class=n-a></a>18.29</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6247 class=n-a></a>7.00</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6250 class=n-a></a>-11.29</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6253 class=n-a></a>-11.29</td><td align=left colspan=1 rowspan=1><a name=d28479e6257 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6259 class=n-a></a></td></tr><tr><a name=d28479e6262 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6264 class=n-a></a>Malaria</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6267 class=n-a></a>2239.72</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6270 class=n-a></a>2276.14</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6273 class=n-a></a>36.42</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6276 class=n-a></a>133.45</td><td align=left colspan=1 rowspan=1><a name=d28479e6280 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6282 class=n-a></a>-97.02</td></tr><tr><a name=d28479e6287 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6289 class=n-a></a>Meningitis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6292 class=n-a></a>91.32</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6295 class=n-a></a>947.94</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6298 class=n-a></a>856.62</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6301 class=n-a></a>856.62</td><td align=left colspan=1 rowspan=1><a name=d28479e6305 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6307 class=n-a></a></td></tr><tr><a name=d28479e6310 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6312 class=n-a></a>Multiple diarrhoeal<br class=br>diseases</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6317 class=n-a></a>13.61</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6320 class=n-a></a>61.02</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6323 class=n-a></a>47.40</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6326 class=n-a></a>47.40</td><td align=left colspan=1 rowspan=1><a name=d28479e6330 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6332 class=n-a></a></td></tr><tr><a name=d28479e6335 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6337 class=n-a></a>Multi-Disease</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6340 class=n-a></a>0.00</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6343 class=n-a></a>74.29</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6346 class=n-a></a>74.29</td><td align=left colspan=1 rowspan=1><a name=d28479e6349 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6352 class=n-a></a>74.29</td><td align=left colspan=1 rowspan=1><a name=d28479e6355 class=n-a></a></td></tr><tr><a name=d28479e6358 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6360 class=n-a></a>Multiple salmonella<br class=br>infections</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6365 class=n-a></a>0.00</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6368 class=n-a></a>37.05</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6371 class=n-a></a>37.05</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6374 class=n-a></a>37.05</td><td align=left colspan=1 rowspan=1><a name=d28479e6378 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6380 class=n-a></a></td></tr><tr><a name=d28479e6383 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6385 class=n-a></a>Multiple vector borne<br class=br>diseases</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6390 class=n-a></a>73.97</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6393 class=n-a></a>91.95</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6396 class=n-a></a>17.98</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6399 class=n-a></a>17.98</td><td align=left colspan=1 rowspan=1><a name=d28479e6403 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6405 class=n-a></a></td></tr><tr><a name=d28479e6408 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6410 class=n-a></a>Mycetoma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6413 class=n-a></a>Not in scope</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6416 class=n-a></a>18.58</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6419 class=n-a></a>18.58</td><td align=left colspan=1 rowspan=1><a name=d28479e6422 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6425 class=n-a></a>18.58</td><td align=left colspan=1 rowspan=1><a name=d28479e6428 class=n-a></a></td></tr><tr><a name=d28479e6432 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6434 class=n-a></a>Non-typhoidal<br class=br>Salmonella (NTS)</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6439 class=n-a></a>289.63</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6442 class=n-a></a>141.66</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6445 class=n-a></a>-147.97</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6448 class=n-a></a>-147.97</td><td align=left colspan=1 rowspan=1><a name=d28479e6452 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6454 class=n-a></a></td></tr><tr><a name=d28479e6457 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6459 class=n-a></a>Onchocerciasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6462 class=n-a></a>104.45</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6465 class=n-a></a>142.33</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6468 class=n-a></a>37.89</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6471 class=n-a></a>37.89</td><td align=left colspan=1 rowspan=1><a name=d28479e6475 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6477 class=n-a></a></td></tr><tr><a name=d28479e6480 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6482 class=n-a></a>Pneumonia</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6485 class=n-a></a>644.20</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6488 class=n-a></a>1249.16</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6491 class=n-a></a>604.95</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6494 class=n-a></a>604.95</td><td align=left colspan=1 rowspan=1><a name=d28479e6498 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6500 class=n-a></a></td></tr><tr><a name=d28479e6503 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6505 class=n-a></a>Reproductive Health</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6508 class=n-a></a>908.55</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6511 class=n-a></a>1579.86</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6514 class=n-a></a>671.31</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6517 class=n-a></a>485.50</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6521 class=n-a></a>185.81</td><td align=left colspan=1 rowspan=1><a name=d28479e6524 class=n-a></a></td></tr><tr><a name=d28479e6527 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6529 class=n-a></a>Rheumatic fever</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6532 class=n-a></a>111.00</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6535 class=n-a></a>222.03</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6538 class=n-a></a>111.02</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6541 class=n-a></a>111.02</td><td align=left colspan=1 rowspan=1><a name=d28479e6545 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6547 class=n-a></a></td></tr><tr><a name=d28479e6550 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6552 class=n-a></a>Rotavirus</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6555 class=n-a></a>618.55</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6558 class=n-a></a>976.35</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6561 class=n-a></a>357.80</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6564 class=n-a></a>357.80</td><td align=left colspan=1 rowspan=1><a name=d28479e6568 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6570 class=n-a></a></td></tr><tr><a name=d28479e6574 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6576 class=n-a></a>Schistosomiasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6579 class=n-a></a>830.37</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6582 class=n-a></a>407.38</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6585 class=n-a></a>-422.98</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6588 class=n-a></a>-422.98</td><td align=left colspan=1 rowspan=1><a name=d28479e6592 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6594 class=n-a></a></td></tr><tr><a name=d28479e6597 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6599 class=n-a></a>Shigellosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6602 class=n-a></a>855.13</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6605 class=n-a></a>824.27</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6608 class=n-a></a>-30.86</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6611 class=n-a></a>-30.86</td><td align=left colspan=1 rowspan=1><a name=d28479e6615 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6617 class=n-a></a></td></tr><tr><a name=d28479e6620 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6622 class=n-a></a>Trachoma</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6625 class=n-a></a>74.06</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6628 class=n-a></a>40.55</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6631 class=n-a></a>-33.51</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6634 class=n-a></a>-33.51</td><td align=left colspan=1 rowspan=1><a name=d28479e6638 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6640 class=n-a></a></td></tr><tr><a name=d28479e6643 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6645 class=n-a></a>Trichuriasis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6648 class=n-a></a>17.60</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6651 class=n-a></a>17.58</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6654 class=n-a></a>-0.02</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6657 class=n-a></a>-0.02</td><td align=left colspan=1 rowspan=1><a name=d28479e6661 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6663 class=n-a></a></td></tr><tr><a name=d28479e6666 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6668 class=n-a></a>Tuberculosis</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6671 class=n-a></a>2569.48</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6674 class=n-a></a>2641.61</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6677 class=n-a></a>72.13</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6680 class=n-a></a>238.04</td><td align=left colspan=1 rowspan=1><a name=d28479e6684 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6686 class=n-a></a>-165.91</td></tr><tr><a name=d28479e6690 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6692 class=n-a></a>Typhoid &amp; paratyphoid</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6695 class=n-a></a>433.10</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6698 class=n-a></a>638.20</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6701 class=n-a></a>205.09</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6704 class=n-a></a>205.09</td><td align=left colspan=1 rowspan=1><a name=d28479e6708 class=n-a></a></td><td align=left colspan=1 rowspan=1><a name=d28479e6710 class=n-a></a></td></tr><tr><a name=d28479e6714 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6716 class=n-a></a><b>TOTAL</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6720 class=n-a></a><b>16348.78</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6724 class=n-a></a><b>21027.18</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6728 class=n-a></a><b>4678.39</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6732 class=n-a></a><b>3521.19</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6737 class=n-a></a><b>1877.10</b></td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6741 class=n-a></a><b>-719.90</b></td></tr></tbody></table></div><p class="" id=d28479e6749>The changes in classification for the eight diagnostic candidates (<a href="#T7">Table 7</a>) from simple platform development in the direct comparison 2019 pipeline to assay development in the complete 2019 pipeline reduced the overall cost by $719 million. This cost reduction is due to the cost per phase being lower for assay development classification than the cost per phase for simple platform development classification for diagnostics in the P2I.v2 model.</p><p class="" id=d28479e6755>Based on the complete 2019 pipeline analysis, <a href="#T12">Table 12</a> summarizes the changes in cost by disease based on the changes in the pipeline, scope expansion and classification changes. In the complete 2019 pipeline, of the total cost, 62% ($12.9 billion) would be for phase III candidates, 22% ($4.7 billion) for phase II candidates, 4% ($921 million) for phase I candidates and 12% ($2.5 billion) for pre-clinical candidates. Furthermore, in the complete 2019 pipeline, over 75% of the cost ($15.9 billion) would be incurred during the first five years.</p></div><div class=section><a name=d28479e6762 class=n-a></a><h3 class=section-title>(viii) Results of the sensitivity analysis for moving current candidates through the pipeline</h3><p class="" id=d28479e6767>For the direct comparison 2019 pipeline, the sensitivity analysis estimated that the total cost to move the current candidates through the pipeline ranges from $16.4 billion to $23.8 billion and the expected launches range from 150 to 240 (<a href="#T13">Table 13</a>). For the complete 2019 pipeline, based on the sensitivity analysis results, the total cost to move the current products to launch ranges from $17.3 billion to $25.2 billion and the expected launches range from 159 to 256 (<a href="#T14">Table 14</a>).</p><a name=T13 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 13. Sensitivity analysis for the 2019 direct comparison pipeline.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e6787 class=n-a></a><thead><a name=d28479e6789 class=n-a></a><tr><a name=d28479e6791 class=n-a></a><th align=left colspan=1 rowspan=1 valign=middle><a name=d28479e6793 class=n-a></a>Parameters</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e6796 class=n-a></a>Percent change from baseline</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e6799 class=n-a></a>Estimated cost<br class=br>($, millions)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e6804 class=n-a></a>Estimated number of<br class=br>product launches</th></tr></thead><tbody><a name=d28479e6811 class=n-a></a><tr><a name=d28479e6813 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6815 class=n-a></a>Baseline</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6818 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6820 class=n-a></a>19,869.98</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6823 class=n-a></a>196</td></tr><tr><a name=d28479e6827 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6829 class=n-a></a>Probability of success</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6832 class=n-a></a>Low (-10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6835 class=n-a></a>18,254.67</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6838 class=n-a></a>150</td></tr><tr><a name=d28479e6842 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6844 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6846 class=n-a></a>High (+10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6849 class=n-a></a>21,666.15</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6852 class=n-a></a>240</td></tr><tr><a name=d28479e6856 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6858 class=n-a></a>Average cost per<br class=br>phase</td><td align=left colspan=1 rowspan=1 valign=bottom><a name=d28479e6863 class=n-a></a>Low (-10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6866 class=n-a></a>17,882.98</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6869 class=n-a></a></td></tr><tr><a name=d28479e6872 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6874 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6876 class=n-a></a>High (+10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6879 class=n-a></a>21,856.98</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e6882 class=n-a></a></td></tr><tr><a name=d28479e6886 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6888 class=n-a></a>Combined</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6891 class=n-a></a>Low (-10% for both parameters)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6894 class=n-a></a>16,429.20</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6897 class=n-a></a>150</td></tr><tr><a name=d28479e6901 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6903 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6905 class=n-a></a>Intermediate 1 (cost +10%, probability of<br class=br>success -10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6910 class=n-a></a>20,080.13</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6913 class=n-a></a>150</td></tr><tr><a name=d28479e6917 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6919 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6921 class=n-a></a>Intermediate 2 (cost -10%, probability of<br class=br>success +10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6926 class=n-a></a>19,499.53</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6929 class=n-a></a>240</td></tr><tr><a name=d28479e6933 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6935 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6937 class=n-a></a>High (+10% for both parameters)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6940 class=n-a></a>23,832.76</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6943 class=n-a></a>240</td></tr></tbody></table></div><a name=T14 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 14. Sensitivity analysis for the complete 2019 pipeline analysis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e6961 class=n-a></a><thead><a name=d28479e6963 class=n-a></a><tr><a name=d28479e6965 class=n-a></a><th align=left colspan=1 rowspan=1 valign=middle><a name=d28479e6967 class=n-a></a>Parameters</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e6970 class=n-a></a>Percent change from baseline</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e6973 class=n-a></a>Estimated cost<br class=br>($, millions)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e6978 class=n-a></a>Estimated number<br class=br>of product launches</th></tr></thead><tbody><a name=d28479e6985 class=n-a></a><tr><a name=d28479e6987 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6989 class=n-a></a>Baseline</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e6992 class=n-a></a></td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6994 class=n-a></a>21,027.18</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e6997 class=n-a></a>207</td></tr><tr><a name=d28479e7001 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7003 class=n-a></a>Probability of success</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7006 class=n-a></a>Low (-10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7009 class=n-a></a>19,215.54</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7012 class=n-a></a>159</td></tr><tr><a name=d28479e7016 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7018 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7020 class=n-a></a>High (+10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7023 class=n-a></a>23,043.73</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7026 class=n-a></a>256</td></tr><tr><a name=d28479e7030 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7032 class=n-a></a>Average cost per<br class=br>phase</td><td align=left colspan=1 rowspan=1 valign=bottom><a name=d28479e7037 class=n-a></a>Low (-10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7040 class=n-a></a>18,924.46</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e7043 class=n-a></a></td></tr><tr><a name=d28479e7046 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7048 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7050 class=n-a></a>High (+10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7053 class=n-a></a>23,129.90</td><td align=right colspan=1 rowspan=1 valign=top><a name=d28479e7056 class=n-a></a></td></tr><tr><a name=d28479e7060 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7062 class=n-a></a>Combined</td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7065 class=n-a></a>Low (-10% for both parameters)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7068 class=n-a></a>17,293.98</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7071 class=n-a></a>159</td></tr><tr><a name=d28479e7075 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7077 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7079 class=n-a></a>Intermediate 1 (cost +10%, probability of<br class=br>success -10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7084 class=n-a></a>21,137.09</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7087 class=n-a></a>159</td></tr><tr><a name=d28479e7091 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7093 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7095 class=n-a></a>Intermediate 2 (cost -10%, probability of<br class=br>success +10%)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7100 class=n-a></a>20,739.35</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7103 class=n-a></a>256</td></tr><tr><a name=d28479e7107 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7109 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7111 class=n-a></a>High (+10% for both parameters)</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7114 class=n-a></a>25,238.99</td><td align=right colspan=1 rowspan=1 valign=bottom><a name=d28479e7117 class=n-a></a>256</td></tr></tbody></table></div></div><div class=section><a name=d28479e7125 class=n-a></a><h3 class=section-title>(ix) Estimated costs to launch missing products</h3><p class="" id=d28479e7130>Our first study using the P2I.v2 tool, based on the 2017 pipeline portfolio review, suggested that there would be 18 “missing products”, which were identified using the list of needed priority products outlined in CIH report<sup><a href="#ref-6">6</a></sup>. In the 2017 analysis, the estimated cost for launching these 18 missing products was between $13.6 billion and $21.6 billion, depending on the complexity of the product.</p><p class="" id=d28479e7137>In the 2019 analysis, the model projects that there are likely to be launches of HIV and TB vaccines and, as a result, there would now be 16 missing products. Since the number of candidates do not change for the 16 missing product categories between the 2019 direct comparison pipeline and the complete 2019 pipeline, the missing products analysis is applicable to both pipelines. To launch one of each of the 16 key missing products, starting from pre-clinical phase, we estimate the costs to be between $5.5 billion (assuming lowest complexity products) and $14.2 billion (assuming highest complexity products). <a href="#T15">Table 15</a> shows the summary of these costs by disease and archetype. The ranges are calculated using the sensitivity analysis described in sub-section (vi) of the Methods.</p><a name=T15 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 15. Additional number of candidates needed to achieve one launch and the costs to launch 16 missing products.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d28479e7154 class=n-a></a><thead><a name=d28479e7156 class=n-a></a><tr><a name=d28479e7158 class=n-a></a><th align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7160 class=n-a></a>Disease</th><th align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7163 class=n-a></a>Product type</th><th align=left colspan=1 rowspan=1 valign=top><a name=d28479e7166 class=n-a></a>Additional no. of<br class=br>candidates needed<br class=br>at preclinical phase</th><th align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7173 class=n-a></a>Cost (US $, millions)</th></tr></thead><tbody><a name=d28479e7178 class=n-a></a><tr><a name=d28479e7180 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7182 class=n-a></a>Tuberculosis</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7185 class=n-a></a>NCE Complex</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7188 class=n-a></a>6 (4-9)</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7191 class=n-a></a>109.9 (68.3-158.4)</td></tr><tr><a name=d28479e7195 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7197 class=n-a></a>Malaria</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7200 class=n-a></a>Vaccine - unprecedented</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7203 class=n-a></a>144 (98-219)</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7206 class=n-a></a>3276.7 (2141.6-5185.3)</td></tr><tr><a name=d28479e7210 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7212 class=n-a></a>Hepatitis C</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7215 class=n-a></a>Vaccine - simple</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7218 class=n-a></a>8 (5-12)</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7221 class=n-a></a>296.2 (216.1-371.7)</td></tr><tr><a name=d28479e7225 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7227 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7229 class=n-a></a>Vaccine - complex</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7232 class=n-a></a>35 (24-53)</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7235 class=n-a></a>1068.2 (735.7-1577.2)</td></tr><tr><a name=d28479e7239 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7241 class=n-a></a>Multiple diarrheal diseases</td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7244 class=n-a></a>Vaccine - simple</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7247 class=n-a></a>11 (8-17)</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7250 class=n-a></a>407.3 (313.3 - 538.7)</td></tr><tr><a name=d28479e7255 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7257 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7259 class=n-a></a>Vaccine - complex</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7262 class=n-a></a>33 (22-50)</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7265 class=n-a></a>1007.2 (691.5-1482.5)</td></tr><tr><a name=d28479e7269 class=n-a></a><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7271 class=n-a></a>12 neglected tropical<br class=br>diseases<a href="#TFN1">*</a></td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7278 class=n-a></a>NCE Simple</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7281 class=n-a></a>109 (74-164)</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7284 class=n-a></a>1490.1 (1025.1 - 2061.2)</td></tr><tr><a name=d28479e7288 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d28479e7290 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=middle><a name=d28479e7292 class=n-a></a>NCE Complex</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7295 class=n-a></a>473 (320-721)</td><td align=center colspan=1 rowspan=1 valign=middle><a name=d28479e7298 class=n-a></a>8621.2 (5772.7-13389.9)</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d28479e7306 class=n-a></a><p id=TFN1> * These diseases are Buruli ulcer, Chagas disease, dengue, hookworm, human African trypanosomiasis (HAT), leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis, schistosomiasis, trachoma and trichuriasis</p></div></div></div><p class="" id=d28479e7314>For the 16 missing products, about 70% of the costs would be incurred during the first five years of product development. Therefore, the costs for the first five years range between $3.85 billion and $9.94 billion.</p><p class="" id=d28479e7318>Over the next five years, the combined cost to move all current candidates through the pipeline and to launch a product each for 16 “missing products” ranges between $19.7 to $25.8 billion, or $3.9 to $5.2 billion per year.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28479e7325>Discussion</h2><p class="" id=d28479e7328>Our study found that the product development R&amp;D pipeline for poverty-related and neglected diseases has grown by more than a quarter in just two years, driven in particular by the global response to 2018–19 outbreaks of Ebola virus disease (EVD), as well as reproductive health, TB and malaria. As a result, the number of expected new product launches expected based on the 2019 pipeline increased by half compared to 2017, while the cost of advancing the pipeline increased by a quarter. Most of the increase in the number of pipeline candidates and the number of launches was in diagnostics, but most of the increased (and overall) costs were associated with vaccine development. The distribution of the R&amp;D pipeline broadly aligns with the landscape of funding going to neglected diseases as assessed in the G-FINDER reports.</p><div class=section><a name=d28479e7331 class=n-a></a><h3 class=section-title>Changes in the pipeline from 2017 to 2019</h3><p class="" id=d28479e7336>At August 31, 2019, there were 754 product candidates that fell within the study scope and had sufficient publicly available information to allow them to be entered into the P2I.v2 model. Of these 754 candidates, 690 were in disease and product areas that were included in our 2017 review, representing an increase of 152 candidates (or 28%) since 2017.</p><p class="" id=d28479e7339>The pipeline growth was primarily in just four areas. Ebola, reproductive health, TB and malaria collectively accounted for 130 (86%) of the 152 additional candidates. The increase in pipeline candidates occurred for all archetypes except for NCEs, but the largest increases were in diagnostics (up by 67 candidates, a 66% increase) and vaccines (up by 48 candidates, a 23% increase), which together accounted for more than three quarters (76%) of the overall increase in product candidates.</p><p class="" id=d28479e7342>Ebola alone was responsible for a significant proportion (41%) of the total growth of the R&amp;D pipeline between 2017 and 2019. The number of candidates in the pipeline for Ebola increased fourfold in this period, reflecting the robust international response to two outbreaks of EVD in the Democratic Republic of the Congo (DRC) in 2018–19, the second of which – originating in North Kivu province – became the second largest EVD outbreak on record<sup><a href="#ref-9">9</a></sup>.</p><p class="" id=d28479e7349>Although TB and malaria were among the diseases to see the most significant pipeline growth, the surge in candidates for Ebola and reproductive health helped reduce the degree to which the pipeline is dominated by HIV/AIDS, TB and malaria. While HIV/AIDS, TB and malaria still collectively accounted for close to half of all candidates in the pipeline in 2017, this proportion was down from 57% of candidates in 2017. From 2017 to 2019, the vaccine pipeline for malaria and TB was essentially stagnant, with each disease registering an increase of just a single candidate between 2017 and 2019. </p><p class="" id=d28479e7353>It is concerning that the size of the R&amp;D pipeline for diarrheal diseases, salmonella infections, helminth infections and kinetoplastid infections either fell or was at best unchanged from 2017 to 2019. Of the 35 diseases included in the 2017 review, 15 still had fewer than four candidates each in the pipeline in 2019. Many of these are neglected tropical diseases, whose funding <a target=xrefwindow href="https://s3-ap-southeast-2.amazonaws.com/policy-cures-website-assets/app/uploads/2020/02/11150341/G-Finder2019.pdf" id=d28479e7355>has remained basically flat over the course of the last decade</a>, while funding for HIV/AIDS, TB, malaria and Ebola has grown significantly. Also concerning is the fact that there was no increase in the number of NCE candidates in the R&amp;D pipeline (in fact there were two fewer in 2019 than in 2017), despite the overall pipeline growing by more than a quarter. There was a roughly even split in the number of new candidates in early-stage development and those in clinical trials or field development.</p></div><div class=section><a name=d28479e7360 class=n-a></a><h3 class=section-title>Launches and missing products</h3><p class="" id=d28479e7365>The model suggests that the 754 candidates currently in the pipeline will deliver 207 launch-ready health technologies targeting poverty-related and neglected diseases. Looking just at the “apples-to-apples” subset, the 690 candidates in the direct comparison pipeline would be expected to deliver 196 launches, an increase of more than half (53%, an additional 68 launches) compared to the 2017 review.</p><p class="" id=d28479e7368>Diagnostics accounted for the vast majority of the increase in expected launches in 2019 over 2017, mostly for assays rather than platforms. This increase reflected the large number of candidates entering the pipeline (especially in Ebola and TB), as well as effect of underlying assumptions of the P2I.v2 model, which applies a high probability of success for diagnostics development. More than half of the increase was for just three diseases: Ebola (up 18, 23%), TB (up 13, 37%) and malaria (up 11, 41%).</p><p class="" id=d28479e7371>As with the pipeline distribution, expected launches are less concentrated on HIV/AIDS, TB and malaria than in the 2017 review, but again this is largely due to the surge in Ebola pipeline activity between 2017 and 2019, reflecting the coordinated global response towards unmet R&amp;D needs to contain two back-to-back EVD outbreaks in the DRC in 2018. Based on the pipeline as of August 31, 2019, the model predicts three launch-ready Ebola vaccines. One Ebola vaccine, Merck’s Ervebo, was approved by both <a target=xrefwindow href="https://ec.europa.eu/commission/presscorner/detail/en/IP_19_6246" id=d28479e7373>the European Commission</a> and <a target=xrefwindow href="https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health" id=d28479e7376>the U.S. Food and Drug Administration</a> in late 2019. Another investigational vaccine, Janssen’s MVA-BN-Filo, is currently deployed in East and Central Africa as part of an expanded response to the DRC outbreak, and has been <a target=xrefwindow href="https://www.jnj.com/johnson-johnson-announces-submission-of-european-marketing-authorisation-applications-for-janssens-investigational-ebola-vaccine-regimen" id=d28479e7379>submitted to the European Medicines Agency</a> for regulatory approval.</p><p class="" id=d28479e7383>The global estimate of launch-ready HIV/AIDS products decreased from 23 in the 2017 review to 19 in the 2019 review, due to a drop in the number of HIV/AIDS NCE candidates in the pipeline. This drop reflected both the successful approval of several late-stage NCE candidates since 2017 and a lack of new candidates entering the pipeline; however, it must be noted that the HIV/AIDS therapeutics category has strict inclusion restrictions in the G-FINDER scope.</p><p class="" id=d28479e7387>One of the most significant changes in the 2019 review compared to the 2017 review is the estimated launch of vaccines for HIV/AIDS and TB by 2031 (the 2017 pipeline would not have led to these two launches<sup><a href="#ref-6">6</a></sup>). This is a positive reflection of progress in the pipeline for these two areas since our last review, but it is worth emphasizing that the P2I model makes no assessment of the appropriateness of the projected launch-ready candidate, nor of any additional research that may be required to support product introduction. So while the model predicts the likely launch of a TB vaccine, the profile of the most advanced candidates in the pipeline suggest that – at the date of the launch projected by the model – such a vaccine may only be approved for use in limited populations. In the case of HIV/AIDS, caution may be warranted given that thus far no candidate has been able to match even the 31% efficacy achieved in <a target=xrefwindow href="https://www.iavireport.org/articles/1833-special-report-thai-trial-results" id=d28479e7393>the 2009 RV144 Thai Phase III clinical trials</a>, and that during the preparation of this report one of the two most advanced HIV vaccine candidates in the pipeline (a modified version of the RV144 vaccine regimen) <a target=xrefwindow href="https://www.nih.gov/news-events/news-releases/experimental-hiv-vaccine-regimen-ineffective-preventing-hiv" id=d28479e7396>was found to be ineffective</a>.</p></div><div class=section><a name=d28479e7401 class=n-a></a><h3 class=section-title>TDR Health Product Portfolio Directory</h3><p class="" id=d28479e7406>In May 2019, TDR launched the Health Product Profile Directory (HPPD), described as an “online database describing 8–10 key characteristics (such as target population, measures of efficacy and dosage) of product profiles for medicines, vaccines, diagnostics and other products that are intended to be accessed by populations in low- and middle-income countries.”<sup><a href="#ref-10">10</a></sup></p><p class="" id=d28479e7412>Out of the 50 WHO-authored target product profiles (TPPs) contained in the HPPD, 28 align with the scope of this study, covering 11 diseases. Whilst not all areas with the largest pipelines have WHO-authored TPPs, most of the areas for which WHO-authored TPPs exist have healthy pipelines.</p><p class="" id=d28479e7415>The continued expansion of the TB diagnostics pipeline (which grew by 50% between 2017 and 2019) is a case in point, but also one that highlights a potential imbalance in the current pipeline. In 2014, the WHO published a report of a consensus meeting highlighting high-priority TPPs for new TB diagnostics, divided into four use cases: (a) a sputum-based test to detect pulmonary TB; (b) a rapid biomarker-based non-sputum-based test; (c) a drug-susceptibility test; and (d) a community-based triage or referral test for identifying people suspected of having TB. In 2019, almost two-thirds (21, 64%) of all diagnostics in late-stage development for TB are rapid drug susceptibility tests; this is compared to just four rapid biomarker-based non-sputum-based test, two triage tests and a single sputum-based test to detect pulmonary TB (the remaining five late-stage candidates are not indicated for a specific TPP).</p><p class="" id=d28479e7418>Further work to map the pipeline against the TPPs in the HPPD would provide useful insights into the nature of the R&amp;D pipeline.</p></div><div class=section><a name=d28479e7423 class=n-a></a><h3 class=section-title>New cost estimates</h3><p class="" id=d28479e7428>Overall, the P2I.v2 model suggests that advancing the current pipeline of 754 candidates to deliver 207 launch-ready health technologies would cost an estimated $21 billion by 2031. More than half of the total amount ($12 billion, 59%) of the cost of advancing the candidates is projected to be spent during the first three years (2020–2022), at an average cost of $3.9 billion per year.</p><p class="" id=d28479e7431>Half of the projected costs ($10 billion, 50%) were for four diseases: Ebola ($2.8 billion, 13%), HIV/AIDS ($2.7 billion, 13%), TB ($2.6 billion, 13%) and malaria ($2.3 billion, 11%). Development of the candidates for the remaining 37 diseases each accounted for less than 10% of the total costs, most of which had less than 1% of the total share of costs.</p><p class="" id=d28479e7434>From an archetype perspective, the main driver of the cost of development were vaccines, which accounted for almost two-thirds ($13 billion, 61%) of the total projected cost through to 2031. This was followed by diagnostics ($2.6 billion, 12%), NCEs ($2.0 billion, 9.6%), biologics ($1.9 billion, 9.3%), repurposed drugs ($1.5 billion, 7.3%) and vector control products ($79 million, 0.4%).</p><p class="" id=d28479e7437>Looking just at the “apples-to-apples” subset, the P2I.v2 model suggests that advancing the pipeline of 690 candidates to deliver 196 launch-ready health technologies would cost an estimated $19.9 billion by 2031. This represents an increase of $3.5 billion (up 22%) over the estimate from the 2017 pipeline review.</p><p class="" id=d28479e7441>The bulk of this $3.5 billion cost increase was due to an additional $3.1 billion in the cost of advancing vaccine candidates, and almost half (47%) was from the more than doubling of projected costs for advancing Ebola candidates (up $1.7 billion, 145%). This makes sense, as Ebola was responsible for a massive increase in the number of vaccine candidates, many of them in pre-clinical development; however the fate of these early-stage candidates is likely to be affected by the approval of Merck’s Ervebo (and pending likely approval of Janssen’s MVA-BN-Filo), as well as the waning of the current DRC outbreak.</p><p class="" id=d28479e7444>Product development costs also increased dramatically over 2017 for meningitis (up $857 million, from a low base; although this was partly due to better sources, primarily the draft publication of the new <a target=xrefwindow href="https://www.who.int/immunization/research/development/Meningitis_roadmap_June_2019.pdf" id=d28479e7446>2030 global roadmap for meningitis vaccines</a>) and pneumonia (up $605 million, 94%; reflecting new vaccine candidates advancing to Phase III clinical trials). Although malaria and TB account for a significant proportion of the projected costs, there was no significant increase in projected costs for these diseases between 2017 and 2019, with pipeline growth in both diseases being mainly in diagnostics rather than in other more costly archetypes.</p><p class="" id=d28479e7450>The additional cost to launch all 16 “missing products” ranges from $5.5 billion to $14.2 billion, depending on the complexity of the products, around 70% of which would be spent in the first 5 years. Combined with the cost of advancing the current pipeline, this means that in the first 5 years the total estimated costs to move all current candidates through the pipeline and develop the 16 missing products would be around $3.9 billion to $5.2 billion per year. This total does not include funding for basic research, discovery, and post-registration studies, all of which are outside the scope of the P2I model cost projections.</p><p class="" id=d28479e7453>How does this compare to current global funding levels? According to the most recent G-FINDER neglected disease report and two soon to be published analyses of R&amp;D for sexual and reproductive health and emerging infectious diseases, total funding for the poverty-related and neglected diseases included in the scope of this paper totaled $3.6 billion in 2018, once funding for basic research and post-registration studies is excluded. This suggests an annual product development funding gap of at least $0.3 billion to $2.6 billion even at current record levels of neglected disease R&amp;D funding.</p></div><div class=section><a name=d28479e7457 class=n-a></a><h3 class=section-title>Strengths of our new study</h3><p class="" id=d28479e7462>To the best of our knowledge, this is the first study to provide time trends for the R&amp;D pipeline of poverty-related and neglected diseases, as well as for product launches and cost estimates. Information on these trends is valuable for R&amp;D funders, researchers, product development partnerships, and policymakers more broadly. Additional diseases were included in this new analysis including the WHO Product Development for Vaccines Advisory Committee’s <a target=xrefwindow href="https://www.who.int/immunization/research/meetings_workshops/1_Giersing_YearinReview_v1_PDVAC_2019.pdf?ua=1" id=d28479e7464>priority pathogens</a>, such as HSV-2 and gonorrhoea. </p><p class="" id=d28479e7468>A major strength of this study, as well as our previous study using the P2I model to examine the 2017 pipeline<sup><a href="#ref-6">6</a></sup>, is that it goes beyond analysing a single therapeutic portfolio (e.g. the pipeline of drugs for TB control<sup><a href="#ref-11">11</a></sup>) to examine the full portfolio of candidates for a very broad range of poverty-related and neglected diseases. This broader approach “aligns with the way in which funders pursue a diversified portfolio of product development projects.”<sup><a href="#ref-6">6</a></sup> Our study helps to identify critical gaps in the global health product development pipeline by showing (a) which diseases and archetypes have few candidates, (b) which product launches are most likely, and (c) which products will probably still be missing based on existing candidates.</p></div><div class=section><a name=d28479e7484 class=n-a></a><h3 class=section-title>Strengths of the P2I.v2 tool</h3><p class="" id=d28479e7489>We have previously described the strengths of the P2I.v2 tool in detail<sup><a href="#ref-6">6</a></sup>. In brief, we highlight three particular strengths here. First, the tool is publicly available online, as are the full details of the pipeline review, model assumptions, and model inputs and outputs. Thus readers can replicate, improve on, and further adapt our work. Second, the tool is highly flexible — users can make modifications to the underlying assumptions to see how such changes would influence the results. Third, the underlying model assumptions are likely to be realistic. These assumptions are based on a very large number of data points (e.g., assumptions on success rates and cycle times were based on data from of 25,000 development candidates), and were validated through examining peer-reviewed literature, industry reports/databases, and expert interviews<sup><a href="#ref-7">7</a></sup>. Our assumptions are roughly in line with reported industry standards (the amount of variation differs by product types)<sup><a href="#ref-12">12</a>,<a href="#ref-13">13</a></sup>.</p></div><div class=section><a name=d28479e7508 class=n-a></a><h3 class=section-title>Limitations of our new study</h3><p class="" id=d28479e7513>The pipeline data used in this study represents a snapshot of the product development pipeline at a single point in time (up to August 31, 2019). Since the pipeline is constantly evolving, any changes—such as the advancement or termination of pipeline candidates—that occurred after this date are not reflected in the pipeline count or the resulting analysis.</p><p class="" id=d28479e7516>Our research was limited to publicly available sources and relied on confirmation from authoritative sources, including the website of the candidate developer, recent reports from international organizations such as WHO and Unitaid, and clinical trial portals. Where we could not confirm the status of a candidate, we excluded it from the active candidate list. The lack of publicly available information on some products under development means that our count of active candidates may be an underestimate. In particular, there is comparatively less information available on pre-clinical candidates, due to the lack of dedicated public registries mirroring those available for clinical trial candidates, and limited sharing of proprietary data by companies. Our reliance on English language sources also means that the undercounting of early-stage R&amp;D activity may disproportionately affect particular countries or regions. Early-stage candidates from the Middle East, Russia and China are likely to be underrepresented.</p><p class="" id=d28479e7519>Our reliance on publicly available data sources also meant that we were unable to identify when each candidate had entered its current phase of development, meaning that from a model input perspective, a candidate that was close to the conclusion of its phase was treated identically to a candidate that had just entered it.</p><p class="" id=d28479e7522>As in our 2017 study<sup><a href="#ref-6">6</a></sup>, our new study uses the consensus prioritization exercise conducted by the 2013 <i>Lancet</i> Commission on Investing in Health to identify the critical “missing” products that the current pipeline of product candidates would fail to deliver, according to the P2I.v2 model. While we believe this remains a robust global consensus, it is now seven years old. In addition, we note that the P2I. v2 model does not account for whether sufficient research and trial site capacity exists to conduct the additional studies that would be needed to deliver these missing products in the timeframe projected by the model.</p></div><div class=section><a name=d28479e7533 class=n-a></a><h3 class=section-title>Limitations of the P2I tool</h3><p class="" id=d28479e7538>We have previously described the limitations of the P2I.v2 tool in detail<sup><a href="#ref-6">6</a></sup>. In brief, we highlight six particular limitations here.</p><p class="" id=d28479e7545>First, the P2I tool is a simple, static, and deterministic model that does not consider (a) possible changes in the product development process, such as improved techniques, novel clinical trial designs (such as highly efficient trials<sup><a href="#ref-14">14</a></sup>), new regulatory pathways, or (b) product-related decisions, such as the decision to discontinue candidates.</p><p class="" id=d28479e7552>Second, the tool requires users to classify every candidate based on the categories available in the model, yet it can be challenging to categorize some candidates into the P2I.v2 archetypes. In particular, there are too few archetypes for diagnostics and vector control products—for example, there are no specific archetype fields for vector control products, with both chemical and biological products included as a single archetype. </p><p class="" id=d28479e7555>Third, the assumptions on probabilities of success for unprecedented vaccines in phases II and III are based on a relatively small number of data points—around 10-25 data points per estimated value.</p><p class="" id=d28479e7559>Fourth, the model assumptions used for each archetype are the same for almost every disease, with just a few exceptions (“unprecedented vaccines” refers to HIV, TB, and malaria vaccines, and there are two TB-specific archetypes, “simple NCE for TB” and “simple biologic for TB”). Therefore, the model does not take into account the specificities involved for developing a product against a specific disease. So, for example, in the model, the costs, success rates, and cycle times per phase for developing a simple vaccine for schistosomiasis would be the same as those for developing a simple vaccine for hepatitis C.</p><p class="" id=d28479e7562>Fifth, the model does not take into account the public health value and clinical utility of a candidate, or the impact of successful product launches on the remaining candidates in the pipeline.</p><p class="" id=d28479e7565>Finally, the model does not include discovery, early pre-clinical development and post-phase III costs such as regulatory review, marketing authorization, Phase IV and pharmacovigilance and other implementation costs. These other costs can be substantial—for example, funders have <a target=xrefwindow href="https://www.gavi.org/sites/default/files/board/minutes/2019/4-dec/07%20%E2%80%93%20Annex%20B%20%E2%80%93%20%20WHO%20Malaria%20Vaccine%20Brief.pdf" id=d28479e7567>already committed $49 million</a> to the first phase of implementation studies for the RTS,S malaria vaccine, with further funding required.</p><p class="" id=d28479e7571>Despite these limitations, efforts are now underway, funded by TDR, to address these weaknesses and to develop further iterations of the tool. TDR is funding many different product development partnerships, including MMV, FIND, and DNDI, to use the tool to analyze their own portfolios; these analyses will also help to refine and improve the tool. TDR is also funding research institutions, such as the Graduate Institute of Geneva, to collect data that can help make further tool modifications. While we did reach out to PDPs to ask them to share new data on product development that could potentially be used to develop a version 3 of the tool (P2I.v3), the PDPs did not have large enough numbers of data points to meaningfully make tool refinements.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28479e7578>Conclusions</h2><p class="" id=d28479e7581>This study has provided additional evidence that the P2I tool can be used effectively to estimate the costs and probable launches associated with moving a portfolio of current candidates for neglected diseases through the pipeline. It can help to identify gaps in the R&amp;D pipeline and to estimate the size of the gap between funding requirements and current levels of R&amp;D investment. Importantly, this study has also shown how the model can be used to estimate the impact of changes in the pipeline over time.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d28479e7588>Data availability</h2><p class="" id=d28479e7591>Open Science Framework: Analysis of the health product pipeline for poverty-related and neglected diseases using the portfolio-to-impact (p2i) modeling tool, <a target=xrefwindow href="https://doi.org/10.17605/OSF.IO/WT6VN" id=d28479e7593>https://doi.org/10.17605/OSF.IO/WT6VN</a><sup><a href="#ref-15">15</a></sup>.</p><p class="" id=d28479e7600>This project contains the following underlying data:</p><div class=list><a name=d28479e7603 class=n-a></a><ul style="list-style-type: none"><li><p id=d28479e7610><span class=label>- </span> Data file 1: Full list of diseases included in 2017 and 2019 pipelines</p></li><li><p id=d28479e7619><span class=label>- </span> Data file 2: Expected launches: unrounded, rounded to nearest integer, and rounded down,</p></li><li><p id=d28479e7628><span class=label>- </span> Data file 3: Candidates in the pipeline for neglected diseases, as of August 31, 2019</p></li><li><p id=d28479e7637><span class=label>- </span> Data file 4: P2I.v2 tool showing anticipated launches and costs by disease and archetype for the 2019 direct comparison pipeline</p></li><li><p id=d28479e7646><span class=label>- </span> Data files 5 and 6: P2I.v2 tool showing anticipated launches and costs by disease and archetype for the 2019 complete pipeline</p></li><li><p id=d28479e7656><span class=label>- </span> Data files 4,5 and 6, which include the P2I modeling tool, are provided in Microsoft Excel format as the files cannot be uploaded in any other format. To use these data files please download the file and use Microsoft Excel software to open the files.</p></li></ul></div><p class="" id=d28479e7661>Data are available under the terms of the <a target=xrefwindow href="http://creativecommons.org/publicdomain/zero/1.0/" id=d28479e7663>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication).</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d28479e7671 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading is-hidden"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d28776>References</h2><div class="section ref-list"><a name=d28479e7671 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d28479e7678 class=n-a></a>Jamison DT, Summers LH, Alleyne G, <i> et al.</i>: Global health 2035: A world converging within a generation. <i>Lancet.</i> 2013; <b>382</b>(9908): 1898–955. <a target=xrefwindow id=d28479e7689 href="http://www.ncbi.nlm.nih.gov/pubmed/24309475">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7692 href="https://doi.org/10.1016/S0140-6736(13)62105-4">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d28479e7701 class=n-a></a>Verguet S, Norheim OF, Olson ZD, <i> et al.</i>: Annual rates of decline in child, maternal, HIV, and tuberculosis mortality across 109 countries of low and middle income from 1990 to 2013: an assessment of the feasibility of post-2015 goals. <i>Lancet Glob Health.</i> 2014; <b>2</b>(12): e698–709. <a target=xrefwindow id=d28479e7712 href="http://www.ncbi.nlm.nih.gov/pubmed/25433625">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7715 href="https://doi.org/10.1016/S2214-109X(14)70316-X">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d28479e7724 class=n-a></a>Boyle CF, Levin C, Hatef A, <i> et al.</i>: Achieving a “Grand Convergence” in Global Health: Modeling the Technical Inputs, Costs, and Impacts from 2016 to 2030. <i>PLoS One.</i> 2015; <b>10</b>(10): e0140092. <a target=xrefwindow id=d28479e7735 href="http://www.ncbi.nlm.nih.gov/pubmed/26452263">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7738 href="https://doi.org/10.1371/journal.pone.0140092">Publisher Full Text </a> | <a target=xrefwindow id=d28479e7742 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4599920">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d28479e7751 class=n-a></a>Watkins DA, Yamey G, Schäferhoff M, <i> et al.</i>: Alma-Ata at 40 years: reflections from the Lancet Commission on Investing in Health. <i>Lancet.</i> 2018; <b>392</b>(10156): 1434–1460. <a target=xrefwindow id=d28479e7762 href="http://www.ncbi.nlm.nih.gov/pubmed/30343859">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7765 href="https://doi.org/10.1016/S0140-6736(18)32389-4">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d28479e7774 class=n-a></a>Beyeler N, Fewer S, Yotebieng M, <i> et al.</i>: Improving resource mobilisation for global health R&amp;D: a role for coordination platforms? <i>BMJ Glob Health.</i> 2019; <b>4</b>(1): e001209. <a target=xrefwindow id=d28479e7785 href="http://www.ncbi.nlm.nih.gov/pubmed/30899563">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7788 href="https://doi.org/10.1136/bmjgh-2018-001209">Publisher Full Text </a> | <a target=xrefwindow id=d28479e7792 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6407558">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d28479e7802 class=n-a></a>Young R, Bekele T, Gunn A, <i> et al.</i>: Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. <i>Gates Open Res.</i> 2018; <b>2</b>: 23. <a target=xrefwindow id=d28479e7813 href="http://www.ncbi.nlm.nih.gov/pubmed/30234193">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7816 href="https://doi.org/10.12688/gatesopenres.12817.2">Publisher Full Text </a> | <a target=xrefwindow id=d28479e7820 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6139384">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d28479e7829 class=n-a></a>Terry RF, Yamey G, Miyazaki-Krause R, <i> et al.</i>: Funding global health product R&amp;D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios. <i>Gates Open Res.</i> 2018; <b>2</b>: 24. <a target=xrefwindow id=d28479e7840 href="http://www.ncbi.nlm.nih.gov/pubmed/30234194">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7843 href="https://doi.org/10.12688/gatesopenres.12816.2">Publisher Full Text </a> | <a target=xrefwindow id=d28479e7847 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6139376">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d28479e7856 class=n-a></a>Mestre-Ferrandiz J, Sussex J, Towse A: The R&amp;D Cost of a New Medicine. <i>Office of Health Economics (OHE) Monograph.</i> 2012. <a target=xrefwindow id=d28479e7861 href="https://www.ohe.org/publications/rd-cost-new-medicine#">Reference Source</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d28479e7870 class=n-a></a>Aruna A, Mbala P, Minikulu L, <i> et al.</i>: Ebola Virus Disease Outbreak — Democratic Republic of the Congo, August 2018–November 2019. <i>MMWR Morb Mortal Wkly Rep.</i> 2019; <b>68</b>(50): 1162–1165. <a target=xrefwindow id=d28479e7881 href="http://www.ncbi.nlm.nih.gov/pubmed/31856146">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7884 href="https://doi.org/10.15585/mmwr.mm6850a3">Publisher Full Text </a> | <a target=xrefwindow id=d28479e7888 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6936163">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d28479e7897 class=n-a></a>Terry RF, Plasència A, Reeder JC: Analysis of the Health Product Profile Directory - a new tool to inform priority-setting in global public health. <i>Health Res Policy Sys.</i> 2019; <b>17</b>(1): 97. <a target=xrefwindow id=d28479e7905 href="http://www.ncbi.nlm.nih.gov/pubmed/31831000">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7908 href="https://doi.org/10.1186/s12961-019-0507-1">Publisher Full Text </a> | <a target=xrefwindow id=d28479e7911 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6909642">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d28479e7920 class=n-a></a>Glickman SW, Rasiel EB, Hamilton CD, <i> et al.</i>: Medicine. A portfolio model of drug development for tuberculosis. <i>Science.</i> 2006; <b>311</b>(5765): 1246–7. <a target=xrefwindow id=d28479e7931 href="http://www.ncbi.nlm.nih.gov/pubmed/16513969">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7934 href="https://doi.org/10.1126/science.1119299">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d28479e7944 class=n-a></a>Schuhmacher A, Gassmann O, Hinder M: A Review of the Pharmaceutical R&amp;D Efficiency: Costs, Timelines, and Probabilities: The Critical Path to Innovation. In: <i>Value Creation in the Pharmaceutical Industry.</i> Edited by Schuhmacher A, Hinder M, Gassmann O. Wiley-VCH Verlag GmbH &amp; Co. KGaA. 2016. <a target=xrefwindow id=d28479e7949 href="https://doi.org/10.1002/9783527693405.ch4">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d28479e7958 class=n-a></a>Hay M, Thomas DW, Craighead JL, <i> et al.</i>: Clinical development success rates for investigational drugs. <i>Nat Biotechnol.</i> 2014; <b>32</b>(1): 40–51. <a target=xrefwindow id=d28479e7969 href="http://www.ncbi.nlm.nih.gov/pubmed/24406927">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7972 href="https://doi.org/10.1038/nbt.2786">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d28479e7981 class=n-a></a>Thorlund K, Golchi S, Haggstrom J, <i> et al.</i>: Highly Efficient Clinical Trials Simulator (HECT): Software application for planning and simulating platform adaptive trials [version 2; peer review: 2 approved, 2 approved with reservations]. <i>Gates Open Res.</i> 2019; <b>3</b>: 780. <a target=xrefwindow id=d28479e7992 href="http://www.ncbi.nlm.nih.gov/pubmed/31259314">PubMed Abstract </a> | <a target=xrefwindow id=d28479e7995 href="https://doi.org/10.12688/gatesopenres.12912.2">Publisher Full Text </a> | <a target=xrefwindow id=d28479e7999 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6556760">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d28479e8008 class=n-a></a>Bandara S, Yamey G, Gunn A, <i> et al.</i>: Analysis of the Health Product Pipeline for Poverty-related and Neglected Diseases Using the Portfolio-to-impact (P2I) Modelling Tool. 2020. <a target=xrefwindow id=d28479e8013 href="http://www.doi.org/10.17605/OSF.IO/WT6VN">http://www.doi.org/10.17605/OSF.IO/WT6VN</a></span></li></ul></div></div></div> </div> <div class=f1r-article-desk> <section class="o-box o-box--medium u-bg--2 u-mt--2"> <h4 class="u-mt--0 u-mb--2 t-h3 u-weight--md">Looking for the Open Peer Review Reports?</h4> <p class="u-mt--0 u-mb--0 t-h4">They can now be found at the top of the panel on the right, linked from the box entitled Open Peer Review. Choose the reviewer report you wish to read and click the 'read' link. You can also read all the peer review reports by <a target=_blank href="https://f1000research.com/articles/9-416/v1/pdf?article_uuid=1fd567b5-6913-4351-9f42-422818aeb4ba">downloading the PDF</a>.</p> </section> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 21 May 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-416&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-416&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Center for Policy Impact in Global Health, Duke Global Health Institute, Duke University, Durham, NC, 27708, USA<br/> <sup>2</sup> Policy Cures Research, Sydney, NSW, 2010, Australia<br/> <p> <div class=margin-bottom> Shashika Bandara <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing – Review & Editing </div> <div class=margin-bottom> Nick Chapman <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Vipul Chowdhary <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Validation, Writing – Review & Editing </div> <div class=margin-bottom> Anna Doubell <br/> <span>Roles: </span> Conceptualization, Investigation, Methodology, Project Administration, Visualization, Writing – Review & Editing </div> <div class=margin-bottom> Amelia Hynen <br/> <span>Roles: </span> Conceptualization, Data Curation, Investigation, Methodology, Writing – Review & Editing </div> <div class=margin-bottom> George Rugarabamu <br/> <span>Roles: </span> Conceptualization, Data Curation, Investigation, Methodology, Validation, Writing – Review & Editing </div> <div class=margin-bottom> Alexander Gunn <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Visualization, Writing – Review & Editing </div> <div class=margin-bottom> Gavin Yamey <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-416/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 21 May 2020, 9:416 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.24015.1">https://doi.org/10.12688/f1000research.24015.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Bandara S <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=26491 data-id=24015 data-downloads="" data-views="" data-scholar="10.12688/f1000research.24015.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-416/v1/pdf?article_uuid=1fd567b5-6913-4351-9f42-422818aeb4ba" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.24015.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Bandara S, Chapman N, Chowdhary V <em>et al.</em> Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool [version 1; peer review: awaiting peer review] <i>F1000Research</i> 2020, <b>9</b>:416 (<a href="https://doi.org/10.12688/f1000research.24015.1" target=_blank>https://doi.org/10.12688/f1000research.24015.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=24015 id=mobile-track-article-signin-24015 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/24015?target=/articles/9-416"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=26491 /> <input name=articleId type=hidden value=24015 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status no-border-and-margin "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <div class=f1r-article-desk-inline><em>AWAITING PEER REVIEW</em></div> <div class="f1r-article-mobile-inline float-right"><em>AWAITING PEER REVIEW</em></div> <span class="circle-icon-small to-right" data-window=about-referee-status title=Help>?</span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 21 May 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-416&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-416&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <div class="p-article__sidebar-highlight u-mb--2"> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="u-ib u-middle"><em>AWAITING PEER REVIEW</em></div> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-416&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-416/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Analysis of the health product pipeline for...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-416/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-416/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-416/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Bandara S et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-416/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-416",
            templates : {
                twitter : "Analysis of the health product pipeline for poverty-related and.... Bandara S et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-416/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Research Article", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/24015/26491")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("articles", "article", "26491");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "69737": 0,
                           "69741": 0,
                           "69743": 0,
                           "69742": 0,
                           "69745": 0,
                           "69744": 0,
                           "63794": 0,
                           "63795": 0,
                           "67381": 0,
                           "63796": 0,
                           "67380": 0,
                           "63797": 0,
                           "67383": 0,
                           "63798": 0,
                           "67382": 0,
                           "67385": 0,
                           "67384": 0,
                           "67386": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "98d595ba-c9be-4b34-b90e-0f9d9e76cc53";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-416.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-416.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-416.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-416.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-416.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>